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Disentangling mutation and selection in human genetic variation: promises and
pitfalls
Ipsita Agarwal
A subset of germline mutations that arise de novo each generation are deleterious
and may cause severe genetic diseases. Predicting where in the genome and how
often we expect to see deleterious mutations requires an understanding both of the
distribution of mutation rates and the distribution of fitness effects in the genome.
Both aspects are addressed in turn in the two projects described in this thesis.
The distribution of mutations in the genome is poorly understood because
germline mutations occur very rarely. In Chapter 1 of this work, we investigated
the sources of mutations by using the spectrum of low-frequency variants in 13,860
human X chromosomes and autosomes as a proxy for the spectrum of germline de novo
mutations. By comparing the mutation spectrum in multiple genomic compartments
on the autosomes and between the X and autosomes that have unique biochemi-
cal and sex-specific properties, we ascribed specific mutation patterns to replication
timing and recombination and identified differences in the types of mutations that
accrue in males and females. Understanding mutational mechanisms provides a basis
for modeling mutation rate variation in the genome, which is ultimately needed to
infer the fitness effects of mutations.
In Chapter 2, we used patterns of human genetic variation at methylated CpG
sites, known to experience mutations at very high rates, to directly learn about the
fitness effects of mutations at these sites. In whole exome sequences now available for
390,000 humans, 99% of putatively-neutral, synonymous CpG sites have experienced
a C>T mutation; at current sample sizes, not seeing a C>T mutation at these sites
indicates strong selection against that mutation. We leveraged the saturation of
neutral C>T mutations and the similarity of mutation rates at methylated CpG sites
across annotations to identify the subset of sites in a given functional annotation of
interest that are likely to be under strong selection. One implication of this work
is that for the vast majority of sites in the genome, there will be little information
about strong selection even in samples that are many times larger than at present;
the distribution of fitness effects at highly mutable CpG sites may then serve as an
anchor for what to expect for other types of sites.
Through the two specific cases described, this work illustrates the potential of large
contemporary repositories of human genetic variation to inform human genetics and
evolution, as well as their limitations in the absence of suitable models of mutation,
selection, and other aspects of the evolutionary process.
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Introduction
The diversity of extant life forms has arisen from a continual influx of genetic nov-
elty in the form of new mutations and the pruning of mutations by natural selection
and random genetic drift over time. For over a century, mathematical models that
describe the evolution of genetic variation as a function of mutation, selection, drift,
and recombination have been foundational to our understanding of the evolutionary
process. These models have provided a framework, for instance, to ask how muta-
tions that are neutral with respect to fitness and mutations that affect the fitness
of organisms in their particular environments are expected to arise and accumulate,
and how these mutations contribute to variation within and between species [1, 2, 3,
4, 5, 6].
It has been of longstanding interest to use these models to learn about the un-
derlying processes of evolution from observed inter-individual variation [7], in part
because of their potential to yield useful biological insights. The ability to sequence
DNA at scale and directly examine genetic variation within and across species has
revolutionized our ability to characterize genetic variation, and to infer parameters
of interest in many cases. For instance, patterns of genetic variation among indi-
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viduals sampled at present have been extensively used to learn about phylogenetic
relationships [8], to infer demographic histories of populations [9, 10, 11], and to de-
tect signatures of selection and thereby identify functionally important genomic loci
and sites of important adaptations [12, 13, 14, 15, 16, 17]. Inferring individual pa-
rameters from genetic variation is difficult because it requires being able to model all
the other parameters correctly, however. For instance, learning about the strength of
selection at a site in the genome requires knowledge of the genealogical history and
the mutation rate at the site, or a comparison to a designated set of neutral sites
which can be assumed to have the same mutation rates and genealogical histories.
In turn, estimating the mutation rate correctly is contingent on being able to
account for the effects of selection and drift, both of which remove mutations from
the population. Early estimates of the mutation rate relied on the mutation-selection
balance at strongly selected loci where drift could be neglected and selection could
be estimated separately: in particular, Haldane obtained an estimate of the mutation
rate from the observed frequency of hemophilia in the population, reasoning that new
mutations that cause hemophilia arise every generation at a rate that balances out
the observed reduction in fecundity of individuals with hemophilia [18]. The gold-
standard approach for a long time involved calculating mutation rates from neutral
divergence between humans and another species for which an estimate of the split
time was available from the fossil record, relying on the rate of mutation being equal
to the rate of neutral substitutions [19, 20]. More recently, the ability to sequence the
genomes of thousands of parent-offspring trios has made it possible to identify de novo
mutations in a single generation[21, 22]. Since these de novo mutations have only
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undergone selection and drift for one generation, they faithfully reflect the mutational
process: only mutations that are embryonic lethal would be missing from these data.
De novo mutation data therefore provide the most direct possible estimate of the
human mutation rate at present: ~1.2×10-8 per bp per generation for a typical site
in the genome [21, 22].
A complication, which has been appreciated for some time, is that the biochemical
propensity of DNA to experience mutations, differs at different types of sites in the
genome; CpG dinucleotides, for instance, have long been known to have a very high
mutation rate [23, 20]. Indeed, variability in mutation rates extends far beyond just
CpG sites, and contributes substantially to differences in levels of genetic variation
at sites across the genome, with so-called “cryptic” variation even within the same
broad sequence contexts [24, 25]. The variation in mutation rates along the genome
makes inference of selection more challenging, since the two contribute to genetic
variation in uncharacterized ways at different sites. For example, the assumption
that one could isolate selection at non-synonymous sites by comparing them with
synonymous sites because these have the same mutation rate on average may not be
warranted, even conditioning on broadly similar base compositions in those groups.
This problem cannot be solved by obtaining direct de novo mutation rate estimates
at a fine scale in the genome because de novo mutations are extremely rare events:
in the largest study to date with 3000 samples, there are only about 200,000 de novo
mutations in total, over 3 billion potential sites in the genome [26]. This has made it
urgent and necessary to more generally understand the sources of mutation, and to
use those to build mutational models that better predict this variability.
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One approach to get at mutational mechanisms is to consider the “mutation spec-
trum”, i.e., the distribution of different types of mutations, since different biochemical
processes that generate or repair DNA lesions often leave distinct mutational signa-
tures in DNA. In recent years, the types of data we can leverage to investigate muta-
tional mechanisms have increased dramatically: in addition to recombination rates,
replication timing and gene expression levels for numerous cell types, new methods
to assay protein-DNA interactions and epigenetic features of sequences have yielded
impressive amounts of information on methylation status, chromatin state, binding
affinities of various proteins, and the incidence of other epigenetic markers at sites
across the genome [27, 28, 29, 26, 30, 31]. Moreover, millions of somatic mutations
have been sequenced in samples of both normal tissues and tumors – examining how
the spectrum of somatic mutations varies with biochemical features such as replica-
tion timing and epigenetic modifications [32, 33, 34, 35, 36, 37, 38, 39, 40, 41], or
across tumors of very different etiologies [42, 43, 44, 45] has been very useful in iden-
tifying mutational signatures of distinct mutagens and repair pathways. The key to
using such an approach to understand sources of mutation in the germline is the abil-
ity to use polymorphism data as a substitute for extremely sparse de novo mutation
data. In large samples, most polymorphisms are rare and recent enough for effects of
direct and indirect selection and biased gene conversion to be minimal; they should
therefore approximate the spectrum of germline mutations reasonably well [46, 47,
48]. Given that whole genome sequences are available for thousands of individuals
[13, 14], the distribution of millions of rare variants across the genome can be used
to investigate associations with various biochemical exposures.
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Taking this approach in the first part of this work, we contrasted diversity lev-
els of different mutation types across regions of the genome that differ with regard
to specific biochemical properties to identify mutation types that are enriched in
association with those biochemical properties. In comparing mutation spectrum dif-
ferences across two compartments, we accounted for mean differences in mutation
rates and genealogical histories across compartments. We found that C>A muta-
tions are strongly associated with late replicating regions of the genome, suggesting
that replication timing contributes substantially to variation across the genome for
this mutation class. As another example, we showed that C>G mutations arise not
only from repair of double-strand break damage in oocytes as previously suggested
[22], but also from the repair of a subset of meiotic double-strand breaks in male germ
cells. Thus, there is an appreciable effect of double-strand breaks on the mutation
spectrum, localized in particular areas of the genome. Finally, relying on the notion
that the X chromosome is enriched for female germline-specific biochemical expo-
sures, we contrasted diversity levels on the X and autosomes, accounting for average
X-autosome differences in replication timing and other features, to find numerous
subtle sex-specific influences on the germline mutation spectrum.
Beyond insights into specific mutational mechanisms for some types of mutations,
our results highlight that rates of different types of mutations are expected to vary
substantially with local distributions of known biochemical features, as well as because
of differences in sex-specific rates of damage and repair in different regions. Because
we compared relative enrichments of mutation types and not mutation rates, we only
learn about patterns of mutation rate variation in a qualitative sense. Nonetheless
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this approach provides a starting point for examining relationships between other
potential mutagenic exposures and mutation rates and for identifying features that
best predict mutation rate variation for different types of mutations.
As an illustration for how information on mutational mechanisms and sources of
variation in mutation rates can be useful, one could consider methylated CpG sites in
the genome, where C>T mutations are known to occur at a rate (~1.2×10-7 per bp
per generation from de novo mutations) that is an order of magnitude higher than any
other type of mutation in the genome [21]. At these sites, a single known mechanism,
i.e., spontaneous deamination of methyl-cytosine, is believed to be predominantly
responsible for their uniquely high mutability [23], and whether or not the CpG is
methylated in the germline is a powerful predictor of the rate of C>T mutations [49].
By conditioning on methylation status, it is possible to identify groups of CpG sites
that are highly mutable, and have similar distributions of mutation rates. Across
such groups of sites then, assuming that they also have similar genealogical histo-
ries, patterns of genetic variation could be directly informative about the strength of
selection.
Given that exome sequences are now available for hundreds of thousands of hu-
mans, we are approaching samples with genealogical histories long enough that in the
absence of natural selection, every site with mutation rate on the order of ~10-7 per bp
per generation will have experienced at least one mutation over that time depth. In
Chapter 2, we show that in a sample of 390,000 individuals, 99% of putatively-neutral,
synonymous CpG sites with high levels of germline methylation have experienced a
C>T mutation. We show through simulations that at current sample sizes, not see-
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ing a C>T mutation at these sites indicates strong selection against that mutation.
We leverage this mutation saturation of putatively neutral sites and the similarity
of mutation rates at methylated CpG sites across annotations to identify the subset
of sites in a given annotation that are likely to be under strong selection. We es-
timate, for example, that ~27% of loss of function mutations and ~6% of missense
mutations are likely to be highly deleterious. One implication of this work is that
for the vast majority of sites in the genome, we will be far from saturation even in
samples that are many times larger than samples at present. Another is that fitness
effects at highly mutable CpG sites may be a useful proxy for what to expect for the
rest of the exome. More generally, we highlight the pitfalls of assigning pathogenic
status to variants of unknown significance based on whether or not those mutations
are observed in reference repositories of human genetic variation in the absence of a
model.
In summary, I present here two specific illustrations of what can be learned about
mutation and selection from large contemporary datasets, and the potential of such
approaches to inform human genetics and evolution, as well as the current and future
challenges associated with them.
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Chapter 1
Signatures of replication timing,
recombination and sex in the
spectrum of rare variants on the
human X chromosome and
autosomes
Published under: Agarwal, I., Przeworski, M. (2019). Signatures of replication timing,
recombination, and sex in the spectrum of rare variants on the human X chromosome




The sources of human germline mutations are poorly understood. Part of the diffi-
culty is that mutations occur very rarely, and so direct pedigree-based approaches
remain limited in the numbers that they can examine. To address this problem, we
consider the spectrum of low frequency variants in a dataset (gnomAD) of 13,860 hu-
man X chromosomes and autosomes. X-autosome differences are reflective of germline
sex differences, and have been used extensively to learn about male versus female mu-
tational processes; what is less appreciated is that they also reflect chromosome-level
biochemical features that differ between the X and autosomes. We tease these compo-
nents apart by comparing the mutation spectrum in multiple genomic compartments
on the autosomes and between the X and autosomes. In so doing, we are able to
ascribe specific mutation patterns to replication timing and recombination, and to
identify differences in the types of mutations that accrue in males and females. In
particular, we identify C>G as a mutagenic signature of male meiotic double strand
breaks on the X, which may result from late repair. Our results show how biochemical
processes of damage and repair in the germline interact with sex-specific life history
traits to shape mutation patterns on both the X chromosome and autosomes.
1.2 Introduction
Germline mutations, the source of all heritable variation, accrue each generation
from accidental changes to the genome during the development of gametes. These
mutations reflect a balance of exogenous damage or endogenous processes that alter
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DNA in the germline, and processes that correctly repair DNA lesions before the next
replication [50]. The biochemical machinery that underlies germline mutagenesis can
be conceptualized as a set of genetic loci that modulate the net mutational input in
each generation, and variants in these loci as “modifiers of mutation” [51, 52]. Since
the activity of distinct biochemical pathways often leaves different signatures in DNA
[43, 42, 53, 54, 44, 45, 55], these modifiers influence the distribution of mutation
types (the “mutation spectrum”), as well as the total number of mutations inherited
by offspring.
The mutational landscape in the germline is also modified by the sex of the par-
ent: in humans, notably, it has long been known that males contribute three times as
many mutations on average as females per generation [56, 21]. As in other mammals,
gametogenesis differs drastically by sex: female germ cells are arrested in meiosis for
much of their development whereas male germ cells enter meiosis late in their devel-
opment [57, 58, 59]. Male germ cells undergo many more cell divisions than female
germ cells; they are also methylated earlier and have higher methylation levels on
average throughout ontogenesis [60]. Due to differences in their cellular biochemistry
at different developmental stages, male and female gametes may be subject to differ-
ent kinds of endogenous and environmental insults, or repair different types of DNA
lesions with varying degrees of efficacy. For example, male gametes may accrue ox-
idative damage due to lack of base excision repair in late spermatogenesis [61]. Males
and females also differ in life history traits such as the timing of puberty and age
of reproduction [62], which modulate the exposure of the gamete to the biochemical
states associated with particular stages of development and thus alter their muta-
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genic impact. In that sense, the sex of the parent as well as variants in loci associated
with sex-specific biochemistry and life history are also modifiers of mutation. The
germline mutation spectrum in each generation is therefore a convolution of the sig-
natures left by biochemical machinery in DNA sequence and the influence of sex on
the developmental trajectories of germ cells.
In principle, it is possible to characterize mutational mechanisms by decomposing
the mutation spectrum into its component signatures. Such an approach has led to a
wealth of insight into the sources of somatic mutations, i.e., mutations that accumu-
late in somatic tissues during normal development or ageing. Distinct signatures of
processes that generate or repair DNA lesions have been identified by analyzing mil-
lions of somatic mutations in their immediate sequence context, across tumor samples
of diverse etiologies [42, 43, 44, 45]. A complementary approach, based on changes
in the mutation spectrum with regional variation in genomic features, has further
illuminated the influence of local replication timing, transcription, chromatin organi-
zation, and epigenetic modifications on somatic mutagenesis [32, 33, 34, 35, 36, 37,
38, 39, 40, 41].
These methods have proved difficult to apply to the germline however, because
each offspring inherits only about 70 de novo mutations on average [22]. Thus, the
most direct approach to the study of germline mutations, the resequencing of pedi-
grees [63, 64, 22, 21, 47], remains limited in its ability to identify determinants of
mutation rate variation. For instance, examining 96 possible mutation types con-
sidered in a trinucleotide context in ~100,000 de novo mutations, the biggest study
to date found only three mutation types for which the proportion transmitted from
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mothers and fathers differed significantly ([22]). Additionally, the mutation patterns
from the three largest de novo mutation studies combined show inconsistent patterns
of correlation to genomic features, for reasons that remain unclear [65].
One way to overcome the limitation of small samples in studies of germline mu-
tation is to use polymorphisms as a proxy for de novo mutations. In large samples,
most polymorphisms are rare and recent enough for effects of direct and indirect se-
lection and biased gene conversion to be minimal; they should therefore recapitulate
the de novo mutation spectrum with reasonable fidelity [46, 47, 48]. The much higher
density of rare variants across the genome can then be used to more robustly investi-
gate associations with genomic features. Using this strategy, a recent study of human
autosomal data identified mutation types and contexts significantly associated with
a variety of genomic features [46]. While the authors suggested putative biochemical
sources for three signatures in the germline based on their similarity to patterns that
have been reported in tumors, it is unclear to what degree these mechanisms can be
directly extrapolated to the germline [66, 67]. Moreover, sex-specific effects on the
mutation spectrum were not considered.
Insight into sex-specific effects can be gained by contrasting polymorphism levels
on the sex chromosomes and autosomes, since autosomes reflect mutational processes
in the male and female germlines equally, while the X chromosome disproportion-
ately reflects the female germline, and the Y chromosome exclusively reflects the
male germline. This approach to studying sex differences has been used extensively;
notably, its application to divergence data provided the first systematic evidence for
a higher contribution of males to mutation in humans and other mammals [68, 69].
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Yet no significant influence of sex on the mutation spectrum was inferred in a recent
comparison of ~3000 rare variants on the X and Y chromosomes [47]. Despite their
importance, therefore, the genesis of germline mutations remains poorly understood
to date, and the role of sex-specific modifiers particularly enigmatic.
To fill this gap, we consider the spectrum of rare polymorphisms across the genome
using genome-wide SNPs in the gnomAD dataset [70, 14]. We compare particular
genomic “compartments”, or units of the genome with unique combinations of bio-
chemical and sex-specific properties, on the X and autosomes; this approach enables
us to tease apart biochemical and sex-specific influences on the germline mutation
spectrum. With over 120 million SNPs to analyze across the genome, we can thus
detect even subtle differences in mutational patterns between genomic compartments.
1.3 Materials and Methods
We use whole genome SNP data from 15,496 individuals made available by the
Genome Aggregation Database (gnomAD), which includes 9,256 Europeans and 4,368
African or African-American individuals [70, 14]. We limit our analysis to the 6,930
female individuals in the dataset to sample X-chromosomes and autosomes in equal
numbers. We then compare the diversity levels of different mutation types in pairs of
genomic compartments (Figure 1.1). In these data, there are ~120 million SNPs, of
which 53% of the variants are singletons (i.e., variants seen only once in the sample,
with an allele count of one), and 11% are doubletons (allele count = 2) (Figure 1.1).
Only about 10% of variants are at frequency 1% or greater; we retain them, given
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that their inclusion does not affect our qualitative results (Supplementary Methods,
Figure 1.6).
Figure 1.1: (a) A schematic of genomic compartments on the X chromosome and au-
tosomes. Three compartments on the X chromosome are depicted: the pseudoautosomal
region (PAR), regions of the X that escape inactivation (E), regions of the X that undergo
inactivation (I). Also depicted are two hypothetical autosomal compartments with distinct
biochemical properties (c1 and c2). Analyses include pairwise comparisons of mutational
patterns between autosomal compartments and between the X chromosome and autosomes.
(b) The frequency spectrum of variants (N = 120,521,915) in the 13,860 chromosomes an-
alyzed. Over two-thirds of mutations are present at three copies or less in the sample.
As in other recent studies, we extract the single base pair flanking sequence on
each side of the variant position using the hg19 reference to obtain mutations in
their trinucleotide context, and combine mutations in reverse complement classes
(for example, the ACG>ATG and CGT>CAT classes are collapsed into the former)
to obtain 96 mutation types. Unless otherwise noted, we treat the major allele as the
ancestral state at a site; however, we obtain similar results using the ancestral allele
and context from the 1000G reconstruction of the ancestral human genome sequence
[71] (Supplementary Methods, Figure 1.7). We include multi-allelic sites (~6% of
the data) by counting the multiple derived alleles separately as if they had occurred
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at separate bi-allelic sites with the same major allele (Supplementary Methods, Fig-
ure 1.8). To obtain the diversity level for each mutation type within a genomic
compartment, we divide the number of segregating sites of a particular type by the
number of mutational opportunities, i.e., sites where a single change could have given
rise to that mutation type; this approach accounts for base composition within a
compartment.
To compare mutation types across two genomic compartments, we normalize the
diversity for each mutation type by the total diversity within each compartment. In
this way, we control for the effect of population genetic processes that affect diversity
across compartments but do so evenly across all mutation types, and isolate differ-
ences in the mutation spectrum; this step is particularly important for comparisons
between the X chromosome and autosomes. For each of 96 mutation types, we test if
the observed relative diversity in the two compartments differs from what would be
expected by chance. To this end, we designate one of the two compartments as the
“test” and the other as the “reference” compartment. Our null expectation is that
the number of mutations of a particular type in the test compartment is binomially
distributed with a mean value proportional to the observed diversity for that type
in the reference compartment, adjusted for overall differences in diversity between
the two compartments (Supplementary Methods). Mutation types are considered
significantly different in their frequencies between the two compartments if the two-
tailed p-value from the binomial test is below the Bonferroni-corrected 5% significance
threshold. This approach implicitly ignores sampling error in the estimate of diversity
of the designated reference compartment; we verify that our results are insensitive
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to this assumption by using alternative approaches to calculate significance that do
not make this assumption, but have other limitations (Supplementary Methods). We
consider the effects of highly mutable types on the distribution of other mutation
types (Supplementary Methods; Figure 1.9); we also consider possible differences
in sequencing error rates between compartments, and replicate our findings in two
alternate datasets (Supplementary Methods; Figure 1.10-Figure 1.12).
1.4 Results and Discussion
Biochemical properties vary along the genome, both on autosomes and the X chro-
mosome. In turn, sex-specific influences from the germline are the same across au-
tosomes, but differ between the X chromosome and autosomes. We therefore first
compare autosomal compartments with distinct biochemical features to illuminate
biochemical influences on the mutation spectrum. Then, by comparing compartments
across the X chromosome and autosomes and accounting for average biochemical dif-
ferences between them, we disentangle sex-specific and biochemical influences on the
mutation spectrum.
1.4.1 Replication timing and its covariates influence the
germline mutation spectrum
We consider autosomal compartments that differ with regard to specific biochemical
properties in the germline. In cases where these data are unavailable for germline
tissue and we are limited to somatic cell lines, we focus on biochemical features that
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have broadly similar distributions across tissue types. Replication timing is consis-
tently an important predictor of local mutation rates [72, 65, 66] in both the soma
and the germline, and broad-scale replication timing maps are relatively concordant
across tissues [27, 73] (Figure 1.13). The observed mutagenic effect of late replica-
tion has been hypothesized to be due to a decline in the efficacy of mismatch repair
with delayed replication, less time for repair, or the accumulation of damage-prone
single-stranded DNA at stalled replication forks [72, 40].
To assess if replication timing affects the germline mutation spectrum, we compare
autosomal regions that differ in their replication timing using available data from
LCL and H9-ESC cell lines [27, 28]. As expected, almost all mutation types are
significantly enriched in late replicating regions relative to early replicating regions
(Figure 1.2, Fig. S9a). In particular, we observe a substantial enrichment of C>A
and T>A mutations in late replicating regions, a pattern also observed by Carlson et
al., 2018 in a different sample of rare variants. Moreover, the mean replication timing
in 1 Mb windows across the genome explains ~60% of the variation in C>A and T>A
enrichment in those windows relative to the autosomal average and between 2% and
26% for all other mutation types (p << 10-5), suggesting that these two mutation
types are particularly sensitive to replication timing ((Figure 1.6, Figure 1.14b, SI
Appendix).
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Figure 1.2: The effect of replication timing on the mutation spectrum at different scales,
using replication timing scores from the LCL cell line. (a) Comparison of the spectrum of 96
mutation types in late replicating (score <= -0.5) autosomal regions relative to early repli-
cating (score >= 0.5) autosomal regions. Positive and negative effects have been separately
ordered by effect size from left to right; only the top 50 significant positive and negative
effects are shown for legibility. The size of the circle reflects the number of mutations of
that type. (b) For each of six mutational classes, the enrichment in 1Mb windows relative
to all other autosomal windows combined, ordered by the mean replication timing. Positive
replication timing scores indicate earlier than average replication. Autosomal windows are
shown in solid light grey circles; windows on the X chromosome have been overlaid in black
hollow circles. (c) For each of six mutational classes, enrichment on individual autosomes
and X relative to all other autosomes combined, ordered by the mean replication timing.
Positive replication timing scores indicate earlier than average replication.
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Because replication timing is correlated with multiple genomic features, including
higher order chromatin structure, epigenetic modifications, and in particular, DNA
methylation at CpG sites, some of the observed patterns could be reflective of these
processes rather than replication per se. To assess the marginal impact of CpG
methylation on the effect of replication timing, we consider early and late replicating
regions within and outside CpG islands, which are regions of CpG hypomethylation
across tissue types [74, 75]. We find that at both CpG sites inside and outside islands,
C>A mutations are enriched in late replicating regions (Figure 1.15), suggesting
that this signal is not due to differences in methylation. Moreover, we also observe
this pattern at non-CpG sites (Figure 1.15).
The association of C>A and T>A mutations with replication timing does not
necessarily imply that they are “replicative” in origin, i.e., due to errors directly
introduced by the replication machinery while copying intact DNA, as they could
also reflect greater unrepaired damage in later replicating regions [40]. In particular,
since C>A mutations are a known consequence of oxidative damage in somatic tissues
[42, 76, 77, 78, 43], it is plausible that these mutations accumulate in regions of late
replication due to greater damage to exposed single-stranded DNA, or poorer repair
in these regions.
Considering other factors shown to influence mutation patterns, we recover a
known signature of CpG methylation: transitions at CpG sites (C>T mutations in
the ACG, CCG, GCG, and TCG trinucleotide contexts), which are thought to be due
to the spontaneous deamination of methyl-cytosine to thymidine, are highly depleted
in the hypomethylated CpG islands compared to the rest of the genome (Figure
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1.16). Similarly, we detect an increase in C>G mutations in a subset of autosomal
regions previously shown to be enriched for clustered C>G de novo mutations (Figure
1.16b). This C>G signature is thought to reflect inaccurate repair of spontaneous
damage-induced double-strand breaks in the germline [22, 49].
Importantly, the impact of these biochemical features on mutation does not av-
erage out across chromosomes. Comparing individual autosomes to all other au-
tosomes reveals ubiquitous variation in the mutation spectrum at the chromosome-
level (Figure 1.16). In particular, individual chromosomes that replicate later on
average show greater enrichment of C>A and T>A mutation types: differences in
mean replication timing for individual autosomes explain ~90% of the variation in
C>A and T>A enrichment at the chromosome level (p << 10-5), while they explain
~50% or less for other mutation types (Figure 1.2). These results demonstrate that
replication timing, and potentially other genomic features such as methylation and
propensity for accidental double strand break damage, lead to chromosome-level dif-
ferences in diversity, hinting at some plausible sources for observed but unexplained
chromosome-level differences in average divergence [67].
1.4.2 Sex-specific influences on the mutation spectrum are
subtle but likely ubiquitous
Next, we assess the impact of sex on the germline mutation spectrum by comparing
mutational patterns on the X chromosome and autosomes. The X chromosome is
disproportionately exposed to mutational processes in the female germline; viewed
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from a population perspective, there are more X chromosomes in females than in
males, but the same number of autosomes in both. Thus, mutation types that arise
more commonly in the female germline are expected to be enriched (and mutation
types that arise more commonly in the male germline depleted) on the X chromosome
relative to autosomes. We account for population-level properties that may affect the
mutation spectrum differently on the X and autosomes (Supplementary Methods).
Having done so, we find most mutation types to be differentially enriched on the X
and autosomes (Figure 1.3).
Importantly, however, these X-autosome differences do not only reflect differences
in male and female mutational processes; given the substantial effect of biochemical
features on mutational patterns observed at the chromosomal scale, they also poten-
tially reflect differences in the distribution of these biochemical features on the X
chromosome and autosomes. For instance, in de novo mutation studies [64, 22], C>A
mutations are found to arise more often in males, suggesting that they should be
depleted on the X. Instead, they are found enriched on the X chromosome relative to
autosomes (Figure 1.3). A possible explanation is that the X accrues excess C>A
mutations because it replicates late in the germline. C>A mutations are known to
be associated with oxidative damage [42, 76, 77, 78, 43], which remains unrepaired
in sperm [61], and is likely repaired at or before the first cell division in the zygote
[79, 80, 81]. Late replication of the X chromosome at this stage, perhaps due to
the inactive status of the paternally inherited X in female embryos [82], could then
indeed be expected to result in an enrichment of C>A mutations on the X relative
to autosomes, despite a primarily male source of damage. This example underscores
21
that accounting for the X-specific effects of biochemical features is key to uncovering
true sex differences in X-autosome comparisons.
Figure 1.3: Comparison of the mutation spectrum on the X chromosome and autosomes.
The pseudoautosomal region (PAR) and CpG sites are excluded from this analysis. Only
significant differences are shown. Positive and negative effects have been separately ordered
by effect size from left to right. The size of the circle reflects the number of mutations of that
type. (a) Enrichment of mutation types on the X chromosome relative to autosomes. (b)
Enrichment of mutation types in the genic compartment of the X chromosome that escapes
inactivation, relative to genic regions on autosomes. Hollow circles represent mutation
types enriched (or depleted) in both the escaped (active) and inactive compartments of
the X relative to autosomes. (c) Enrichment of mutation types in the genic X chromosome
compartment that undergoes X-inactivation, relative to genic regions on autosomes. Hollow
circles represent mutation types enriched (or depleted) in both the escaped (active) and
inactive compartments of the X relative to autosomes. The larger number of significant
differences in (c) compared to (b) likely reflects at least in part the approximately five-fold
greater amount of data in the inactive versus the active genic regions of the X chromosome.
One well-characterized idiosyncratic property of the X is X-inactivation, which
is associated with X-specific changes in methylation, transcriptional activity, and
notably, replication timing: because the inactive X chromosome exhibits a significant
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lag in replication, on average the X replicates later than autosomes [83]. Though X-
inactivation is a short-lived process in the germline—limited to early embryogenesis
in females, and brief meiotic and post-meiotic periods in males [84, 85, 86, 87]—it
could nevertheless lead to observable differences in the mutation spectrum between
different regions of the X. The “active” compartment of the X chromosome, i.e.,
the approximately 15% of the transcribed X that constitutively escapes inactivation
across tissues [88, 89] may therefore differ in its mutation spectrum from the rest of
the X. Comparing autosomes with the inactive and active regions of the X, we find
T>C mutations at GTC sites and C>T types at ACT sites enriched in both active
and inactive regions of the X relative to autosomes and T>G mutations at ATG
sites depleted both in the active and inactive regions of the X relative to autosomes
(Figure 1.3, Figure 1.17). Since these cases cannot be attributed to X-inactivation
and are enriched (or depleted) concordantly on compartments of the X chromosome
that differ in their replication timing, methylation levels and other features, they
are strong candidates for true sex differences in mutation. Given that the genic
compartment known to escape inactivation across tissues is a small fraction of the X
chromosome, there are likely many more subtle ones that we miss.
A complementary approach to minimizing X-specific biochemical influences on
the mutation spectrum of the X in X-autosome comparisons is to consider regions
of the X chromosome that are comparable to autosomes in their average replication
timing. The replication timing on the X chromosome across multiple human cell
lines depends on whether one of the X chromosomes is inactivated (Figure 1.13;
Supplementary Methods) [90, 91, 92, 73, 27, 59]. This observation suggests that
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controlling for replication timing differences between the X chromosome and auto-
somes may also control for the effects of other correlated features, including those
associated with X-inactivation. Using this approach, all three mutation types that
we highlight as putative sex differences based on their differential enrichment in the
active compartment of the X relative to autosomes are also observed as significant
differences between the X chromosome and autosomes (Figure 1.4, Figure 1.18).
That we find the same types with this complementary approach provides further
evidence that they are true sex differences.
We also detect a number of additional differentially enriched types between X and
autosomes after controlling for replication timing differences (Figure 1.4); many of
these types are enriched concordantly in early and late replicating regions of the X
relative to autosomes (Figure 1.19). Assuming that a majority of X-specific effects
are accounted for when we control for replication timing, these types can also be
considered putative sex differences. In that respect, it is noteworthy that C>A mu-
tations are enriched in inactive or late replicating regions of the X, but depleted in
the active or early replicating regions of the X, when compared to autosomes (Figure
1.17,Figure 1.19). This pattern is what we would expect from the combined in-
fluences of a male bias and an effect of replication timing on C>A mutations, as we
suggested earlier.
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Figure 1.4: The mutation spectrum on the X and autosomes matched for average repli-
cation timing. The pseudoautosomal region (PAR) and CpG sites are excluded from this
analysis. (a) Comparison of the mutation spectrum on the X chromosome and autosomes
matched for average replication timing. Only significant differences are shown. Positive
and negative effects have been separately ordered by effect size from left to right. Hollow
circles represent mutation types also enriched (or depleted) in both the active and inactive
compartments of the X relative to autosomes. Crosses denote mutation types reported
as significant sex differences by Jonsson et al., 2017. (b) The X-autosome spectrum for
six mutation classes, controlling for mean replication timing (in red), compared to known
male female differences from Jonsson et al., 2017 (in black). Solid points are statistically
significant differences at the 5% level, accounting for multiple tests.
We further assess these putative sex-specific signatures by comparing them to
results from the largest human pedigree study of de novo mutations to date ([22]).
Among the six broad mutational classes, Jonsson et al. find C>T mutations sig-
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nificantly enriched in maternal, and C>A, C>G, and T>G mutations relatively en-
riched in paternal de novo mutations. The mutational patterns we observe on the
X chromosome and autosomes after controlling for differences in replication timing
are consistent with these effects: we find C>T mutations significantly enriched and
C>A, C>G, and T>G classes significantly depleted on the X chromosome relative
to autosomes ((Figure 1.4, Figure 1.18). Jonsson et al. also find three mutation
types in their trinucleotide context (TCC>TTC, ACC>AAC, ATT>AGT) as signif-
icant sex differences: of these we find two as significant X-autosome differences. As
expected, the maternally enriched TCC>TTC type is relatively enriched on the X
chromosome, and the paternally enriched ACC>AAC type is relatively enriched on
autosomes (Figure 1.4). We do not observe the third type as differentially enriched
on the X and autosomes, possibly because there are genomic features specific to the
X that mask its enrichment in females.
In turn, the types that we identify as putative sex differences from the com-
parison of X active, X inactive and autosomes are not reported as significant sex
differences in Jonsson et al. (2017). The reason may be that most of them reflect
subtle X-autosome differences, with X-enrichment or depletion in the range of 5-10%.
Translating these enrichments into a difference between males and females requires
a full population genetic model, including assumptions about demography and life
history [93]. Nonetheless, such subtle X-autosome differences likely correspond to
small sex differences that current de novo studies are underpowered to detect.
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1.4.3 A subset of meiotic double-strand breaks have the
same mutagenic impact as accidental damage
In the preceding section, we suggested a plausible mechanism through which local
biochemical influences and sex-specific properties of the germline jointly influence
the distribution of C>A mutations on the X chromosome and autosomes. Here we
highlight another mutation type, C>G, which is also distributed in a sex-specific and
chromosome-specific manner, but is largely insensitive to replication timing.
As recently reported, clustered C>G de novo mutations are concentrated in par-
ticular autosomal regions, and the number of such mutations transmitted in each
generation increases exponentially with maternal age at reproduction [22, 49]. Ma-
ternal age at reproduction determines the duration of oocyte arrest, since females are
born with their entire complement of oocytes, which remain in dictyate arrest until
ovulation. Based on the sex-specific patterns of accumulation with age and genomic
properties of these mutations, the authors speculated that the C>G clusters could be
due to the more frequent spontaneous occurrence of damage-induced double strand
breaks (DSBs) in some genomic regions and an increasing rate of such damage in older
oocytes. In this view, C>G mutations are associated with accidental double-strand
break damage in both males and females.
Accidental damage is not the only source of double strand breaks in the germline,
however: during meiosis, double strand breaks are deliberately induced along the
genome, through targeting of PRDM9-binding motifs [94, 95]. These DSBs are re-
paired through the homologous recombination pathway: a small minority are resolved
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through crossovers (COs), which involve exchanges of large segments between homol-
ogous chromosomes, and the rest are thought to be repaired through non-crossover
gene conversion events (NCOGCs), though another small subset may involve non-
homologous end joining and other mechanisms [96, 97]. Potentially, these meiotic
DSBs could have a mutagenic impact similar to that of spontaneous double-strand
breaks; however, a clear mutational pattern common to both has not been seen to
date. For instance, using DMC1 ChIP-Seq data from human spermatocytes, Pratto et
al., 2014 observed C>G enrichment to a small degree around male autosomal hotspots
[29], but the source of these types was not discussed further by the authors, and is
potentially due to overlap with regions of clustered de novo C>G mutations reported
by Jonsson et al., 2017. Another recent study did not find de novo C>G mutations
enriched within autosomal crossover hotspots identified in pedigree studies [26]. We
test if there is indeed an enrichment of C>G mutations associated with meiotic DSBs
by comparing the mutation spectrum within and outside hotspots on autosomes; we
use DMC1 hotspots in males and crossover hotspots in females because we do not
have a map of DMC1-binding in female gametes. Our results are consistent with
previous observations: we do not observe C>G enrichment in autosomal hotspots
for males or females once we exclude regions of clustered de novo C>G mutations
(Figure 1.16, Figure 1.20).
We next consider the X chromosome, which in females recombines like an au-
tosome, but in males is in the unusual position of having no homolog outside the
pseudoautosomal region (PAR). In males as in females, meiotic DSBs are nonetheless
made both inside and outside the PAR [98, 99, 100, 29] Properties of recombination
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events on the X and autosomes differ markedly between sexes however: notably, the
pseudoautosomal region 1 (PAR1), a 2.6 Mb region on the X chromosome, experiences
an obligate crossover in males, but normal levels of recombination in females [101, 98,
102, 103] and in male germ cells, DSBs are repaired late on the X chromosome relative
to autosomes [98, 102, 99, 100, 29]. These considerations raise the possibility that
mutational patterns in hotspots on the X chromosome in males may reflect these
sex-specific features of recombination and behave differently relative to autosomal
hotspots in males, and relative to both X and autosomes in females. To explore this
hypothesis, we compare mutation patterns on autosomes to those in PAR1, which is
exposed to the male and female germlines to the same degree as autosomes (since two
copies are carried by both males and females), and does not undergo X-inactivation
[104]. We find that C>G mutation types are systematically enriched on the PAR1
relative to autosomes (Figure 1.5), indicating that repair of meiotic double-strand
breaks in this region in males is associated with C>G enrichment.
We further characterize the source of the C>G enrichment using DMC1 ChIP-
Seq data from human spermatocytes [29]. The DMC1 signal reflects intermediates
in the homologous recombination pathway; high levels of DMC1-binding can reflect
either an increased frequency of double strand breaks (hotspots of greater intensity)
or a greater duration of intermediates, i.e., a longer time to repair [98, 29]. Using
these data, we find that there is clear C>G enrichment not only in PAR1, but also
in hotspots on the X chromosome outside PAR1; moreover, the enrichment increases
with the strength of the DMC1 signal ((Figure 1.5, Figure 1.20).
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Figure 1.5: Distribution of C>G mutations in genomic compartments relative to auto-
somes. CpG sites are excluded from these analyses. (a) The mutation spectrum on PAR1
relative to autosomes. Only significant differences are shown. Positive and negative effects
have been separately ordered by effect size from left to right. (b) Enrichment of C>G
mutations in DMC1 hotspots of varying intensity on autosomes. For each estimate, the
95% confidence interval from a binomial test is represented by the vertical bars (and is
sometimes too small to be apparent). The horizontal black bar shows the reference, namely
autosomes outside DMC1 hotspots and excluding regions rich in clustered de novo muta-
tions (identified by Jonsson et al., 2017). (c) Enrichment of C>G mutations in DMC1
hotspots of varying intensity on the X chromosome, relative to autosomes outside DMC1
hotspots and excluding autosomal regions rich in clustered de novo mutations. For each
estimate, the 95% confidence interval from a binomial test is represented by the vertical
bars. The reference, same as for (b), is denoted by a horizontal black bar.
That we observe C>G enrichment in male hotspots on the X chromosome but not
in male hotspots of similar average intensities on autosomes (Figure 1.5, Figure
1.20) or in female crossover hotspots on autosomes (Figure 1.20), leads us to specu-
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late that the predominant source of this C>G signature is the delay in repair of DSBs
on the X chromosome relative to autosomes in male meiosis. We note that because
hotspots detected in spermatocytes could also be used in female meiosis [105], with-
out a female-specific map of DMC1 binding, we cannot exclude the possibility that
C>G enrichment is also associated with recombination on the X in females; however,
the observed C>G enrichment in the strongly male-biased hotspot PAR1 (Figure
1.5) supports our conjecture of a male-specific impact of meiotic DSBs on the X, at
least in this region.
One possibility is that the enrichment of C>G mutations stems from a switch in
the repair machinery late in meiosis [106, 107, 108]; DSBs still not repaired by this
stage may be repaired by a more mitotic-like repair pathway, which could potentially
be more mutagenic [107, 109]. Notably, the source of the C>G signature found by
Jonsson et al., 2017 in specific autosomal regions could also be late repair; indeed, if
these areas reflect damage, as the authors surmise, they may only undergo repair later
in meiosis. Thus, a shared biochemical pathway may underlie the mutagenic impact
of both spontaneous and a subset of meiotic DSBs. Moreover, our results illustrate
a subtle sex-specific mutagenic effect of meiotic recombination, whereby the repair
of meiotic DSBs on the X specifically in males gives rise to C>G mutations; in that
sense, components of the recombination machinery that are involved in late repair of
double-strand breaks are sex-specific modifiers of mutation.
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1.5 Implications
By comparing the mutation spectrum across different compartments of the genome,
we identify putative signatures of sex differences in the germline and plausible bio-
chemical sources of mutagenesis. Notably, we show that replication timing affects
the mutation spectrum along the genome and find a mutagenic effect of meiotic re-
combination that is both sex-specific and X-specific, revealing an appreciable effect
of double-strand breaks, both accidental and deliberate, on the mutation spectrum.
Interestingly, our analysis suggests that signatures of sex differences in the
germline are likely abundant, but their contributions to the mutation spectrum are
subtle relative to those of biochemical processes shared in the two sexes. This finding
is hard to reconcile with the idea that male mutations are mostly replication-driven
whereas female mutations reflect a large contribution of spontaneous damage, as
then we might expect substantially different types of mutations inherited from moth-
ers and fathers. Instead, consistent with a greater role of spontaneous damage and its
repair in both male and female germlines [49], our results are most readily explained
if male and female mutational mechanisms are overall highly similar, underpinned by
the shared mechanisms associated with replication, transcription, methylation, and
recombination, and other sources of damage. Subtle differences in the mutation spec-
trum between males and females could then be expected to arise due to sex-specific
rates of damage and repair at different stages in germline development.
These sex differences in germline mutation are modulated by life history traits of
males and females. As one example, the proportion of C>G mutations transmitted in
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a single generation increases with the age of the mother ([22, 49]. Indeed, even when
there are no sex-differences in the biochemical process itself, much of the biochemical
machinery that influences mutation must in theory have subtle sex-specific effects,
simply because sex-specific life history traits modulate exposure to biochemical in-
fluences differently in males and females. Changes in life history traits, or in the
frequency of variants associated with sex-specific life history traits over evolutionary
time could then change the proportion of particular mutation types and thus alter the
mutation spectrum over time. Together with other sex-specific modifiers of mutation,
life history traits likely play a role in the evolution of the mutation spectrum not only
on autosomes, but also on the X chromosome relative to autosomes.
In this respect, we note that a number of recent studies have shown that the
mutation spectrum changes slightly across populations [110, 52, 111, 112]. These
findings have largely been attributed to biochemical modifiers of mutation that alter
the relative rates of different mutation types by influencing the biochemical process
of error/repair over time. Our results highlight that life history traits and other sex-
specific modifiers could potentially result in the same kinds of changes in the mutation
spectrum and the mutation rate over time. Moreover, parental ages of reproduction
explain a large proportion of the observed mutation rate variation among ~1500
individuals at present ([22]). Variants that contribute to sex-specific life history [113,
114] may therefore be a useful starting point to identify genetic sources of inter-
individual variation in the mutation rate in humans.
Beyond these insights into mutagenesis, our analysis makes clear that X-autosome
comparisons of mutation patterns cannot be taken as directly reflective of germline
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sex differences. Though historically comparisons of the sex chromosomes to auto-
somes have been taken to reflect only the effects of sex, mutation patterns on the
X chromosome in fact reflect a convolution of X chromosome specific effects and
sex. Taking this point into consideration may help to explain, for instance, why es-
timates of the male bias in mutation for CpG sites from phylogenetic studies that
used X-autosome comparisons are much lower [115] than those obtained directly from
male-female differences in de novo mutation data (12, [21, 22]).
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1.7 Supplementary Methods
1.7.1 Delineating the set of variants in the gnomAD dataset
We used publicly available whole genome SNP data from 15,496 individuals compiled
and made available by the Genome Aggregation Database (gnomAD), which includes
9,256 Europeans and 4,368 African or African-American individuals [70, 14]. We
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restricted our dataset to a set of good quality SNPs that passed the baseline quality
filter provided by gnomAD, such that there was at least one individual at each site
with a high-quality non-reference genotype: quality-adjusted allele count (AC) > 0,
or equivalently, Filter = “Pass”, DP > 10, GQ > 20, and AB > 0.2 for heterozygotes.
We excluded sites that overlap with indels and CNVs. We retained multi-allelic sites
(6.5% and 5% of the data on the autosomes and X respectively). Since our goal
was to compare genomic compartments, including those on the X chromosome, we
matched the number of X chromosomes and autosomes in our sample by limiting
our analysis to the 6,930 female individuals in the sample (using the quality-adjusted
female allele counts provided). Additionally, we imposed separate filters on the X
chromosome and autosomes so that only variants with an allelic depth within one
standard deviation of the mean allelic depth on the X chromosome (13760 +/- 512)
and autosomes (13753 +/- 562), respectively, were retained in the sample (only about
2.8% of data from both the X-chromosome and autosomes is lost at this step).
1.7.2 Calculating diversity levels for 96 mutation types
Most variants in the gnomAD dataset are extremely rare: about 64% are singletons
and doubletons (i.e., variants seen once or twice in the sample). Only 10% of variants
are at frequency 1% or greater (Fig. 1b); their inclusion does not affect our qualita-
tive results, since they are a small subset of the data, and their mutation patterns are
largely the same as variants at lower frequencies (Figure 1.6); we therefore retain
them. The variants in the gnomAD dataset are called with respect to the human
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reference (hg19). We instead polarized to the major allele in the full sample of 15,496
individuals, so that the minor allele was treated as derived. At multi-allelic sites, we
counted the multiple derived alleles separately as if they had occurred at separate
bi-allelic sites with the same major allele. We obtained similar results (Figure 1.7)
using the ancestral allele and context from the 1000G reconstruction of the ancestral
human genome sequence [71]. As is standard (e.g., Alexandrov et al. 2013; Harris
2015; Harris and Pritchard 2017), we extracted the single base pair flanking sequence
on each side of the variant position using the portion of the hg19 reference callable
in gnomAD to obtain mutations in their trinucleotide context (we substituted the
reference allele with the major allele at variant positions to obtain the correct trin-
ucleotide context at these positions; note that the major allele in this sample only
differs from the reference allele at 1% of variant positions). We combined mutations
in reverse complement classes (for example, the ACG>ATG and CGT>CAT classes
were collapsed into the former) to obtain 96 mutation types. To obtain diversity
levels for each of the 96 mutation types, we divided the number of segregating sites
of a particular type by the number of mutational opportunities at that type of site,
where mutational opportunities are defined as sites at which a single change could
have given rise to the mutation type under consideration (note that there are three
mutational opportunities at each base pair in the genome). By dividing the number
of mutations by the number of possible mutations in each genomic compartment, we
account for base composition differences between compartments.
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1.7.3 Comparing diversity levels between genomic
compartments
In comparing a pair of genomic compartments, we took differences in their population
genetic properties into account. By normalizing the diversity levels for each mutation
type by overall diversity levels for the two compartments, we controlled for the effect
of population genetic processes that affect diversity across compartments but are
expected to do so evenly across all mutation types, allowing us to isolate differences
in the mutation spectrum. This normalization is particularly relevant for comparisons
between the X chromosome and autosomes as, for the same sample size, there are more
neutral segregating sites expected on autosomes: because the autosomes spend more
time in the male germline relative to the X chromosome, they have a higher overall
mutation rate, as well as a slightly larger effective population size due to differences in
the genealogical process between the X-chromosome and autosomes. Suppose that in
an arbitrary genomic compartment “a” with n total mutations (“segregating sites”)
of all types and ni mutations of type i, the proportion of mutation type i is ni⁄n. If
there are di potential sites (“mutational opportunities”) at which this mutation type
could occur, out of d total sites in the compartment, the normalized proportion (or
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In particular, when the two compartments under consideration are the X chromo-
some and autosomes, normalizing by overall diversity allows us to take into account
the different population level effects of demography and life history on these com-
partments, captured in the effective population size (Ne) parameter (under some










where π̄ is mean diversity and µ denotes the mutation rate. In large samples
with recurrent mutations (i.e., repeat mutations or “multiple hits” at the same site),
normalizing by overall diversity does not account fully for population level effects,
particularly for sites with high mutation rates. In particular, at the highly mutable
CpG sites, recurrent mutations are frequently expected in a sample of this size [24,
14]. Because autosomes have a slightly larger effective population size and higher
mutation rate compared to the X, we expect more recurrent mutations at these sites
on autosomes. Although we include multi-allelic sites in our analysis and can there-
fore count mutations to three different alleles at a site, since we only observe allele
frequencies and not haplotypes, we do not see recurrent mutations of the same type
as separate segregating sites. We would consequently under-count recurrent muta-
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tions on autosomes, and may observe an apparent enrichment of these types on the
X-chromosome. For this reason, differences in the relative diversity at CpG sites
on the X chromosome and autosomes must be cautiously interpreted. This concern
applies not just to CpG transitions (C>T mutations at CpG sites), which have the
highest mutation rate, but potentially also to C>A and C>G mutations at CpG
sites, which also have a higher mutation rate than average [20, 116], and for which
we observed a substantial decrease in X-enrichment when we counted multiple alleles
at a site (Figure 1.8). To be conservative, we excluded CpG sites in comparisons
between the X chromosome and autosomes. Including them does not change any
of our qualitative results, however. The explanation is likely that the difference in
effective population size for the X chromosome and autosomes is small, and that the
effect of recurrent mutations on the X-autosome comparison is even smaller. This
minor effect is mitigated further by including visible multi-allelic sites.
1.7.4 Testing for significant differences in the mutation
spectrum between genomic compartments
We tested if mutation type i is distributed the same way in two compartments (a and
b) given what would be expected based on the overall distribution of mutations in the
two compartments. Effectively, we considered the relationship between the following







We designated the larger compartment (i.e., with a greater number of mutational
opportunities) as the reference compartment (for example, in X-autosome compar-
isons, the autosomes were used as reference). We assumed that the number of muta-
tions of a particular type in compartment a (the “test” compartment) is binomially
distributed with a mean value proportional to the observed diversity for that type
in compartment b (the reference compartment), adjusted for overall differences in
diversity between the two compartments:
ni(a) ∼ binom(di(a), fi)
E(ni(a)) = di(a) ∗ fi






The factor fi is the expected diversity level for a given type in the test compart-
ment. For each type, we tested if the observed number of mutations in the test com-
partment differs from the number expected by chance, using the “binom.test” function
in R to obtain p-values. Mutational types were considered significantly different in
their frequencies in the two compartments if the two-tailed p-value from the binomial
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test was below the Bonferroni-corrected 5% significance threshold (=0.05/96). The




We also obtained 95% confidence intervals for the relative enrichment of each type
from the binomial test. We implicitly assumed that mutations of one type do not
impact mutational opportunities of other types. The reason is that because the total
number of mutations is much smaller than the number of mutational opportunities,
an increase in the number of mutations of one type does not appreciably decrease
the mutational opportunities available for other types. We note, however, that the
tests for different mutation types are still not fully independent, because the expected
diversity for each mutation type in the test compartment depends on the overall rel-
ative diversity in the two compartments. If they constitute a large proportion of the
total number of mutations, mutation types that are highly significantly enriched in
one compartment could influence the null distribution for other mutation types and
thus lead to the depletion of these other types in that compartment. In general, we
focused on describing the top signals we observed, which are unlikely to be strongly
affected by this phenomenon. Nevertheless, to assess the impact of this issue, we
implemented a procedure similar to the “forward variable selection procedure” used
by Harris and Pritchard (2017). We ranked mutation types by their p-values in an
initial set of 96 tests. We then sequentially removed the most significant mutation
type and reassessed the other types for significance at each step; mutation types that
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reached significance through interactions with other types should drop out. We note
that re-generating the ratio of expected diversity in two genomic compartments at
each step based on the mutation types remaining in the sample can result in even
more significant differences between compartments. Because mutations at CpG sites
have the largest sample sizes by far, the largest impact of forward variable selection is
observed when CpG transitions are highly enriched in a particular compartment (i.e.,
in non-CpG islands relative to CpG islands); for this analysis we only highlight the
top signals (Figure 1.16). Our other analyses remain qualitatively unchanged by
forward variable selection, and also by excluding CpG sites. The effect of these proce-
dures on our X-autosome comparison is shown in Supplementary Figure 4. We note
that in testing for significant differences in the mutation spectrum between genomic
compartments using a binomial test, as described above, we implicitly ignore sampling
error in the estimate of diversity of the designated reference compartment; we verified
that our results are insensitive to this assumption by using alternative approaches to
calculate significance that do not make this assumption, but have other limitations.
These are described below: First, we bootstrapped the expected distribution of a
particular mutation type in the two compartments using hypergeometric sampling.
For a given mutation type i with sample size ni(= ni(a) + ni(b)), we generated a ran-
dom variable ki for the number of draws in compartment a when ni mutations were
drawn without replacement from the pool of all mutations in both compartments,
n = n(a) + n(b) with n(a) “successes” in compartment a, i.e., ki ∼ Hyper(n, n(a), ni).
The expected distribution of the ratio of mutations of type i in the two compart-
ments, ki
ni−ki , was obtained using 10,000 such trials. We calculated a p-value using
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the rank of the observed relative diversity (adjusted by the ratio of total mutational
opportunities of all types in the two compartments) in the expected distribution. In
this approach, we allowed for uncertainty in the number of mutations of a particular
type in both compartments, but held constant the total diversity in each compart-
ment. Second, we adjusted the number of mutations in one of the compartments by
the ratio of overall diversity in the two compartments, and then applied a chi-squared
test to the 2x2 contingency table (shown below) of the mutations (“successes”) and
the remaining mutational opportunities (“failures”) by compartment. Third, we fit-
ted the same 2x2 contingency table using a binomial glm (with the compartment as
a covariate).
ni(a)/p ni(b)




We compared these methods for three analyses: X vs Autosome, PAR vs Auto-
some, and X-A matched for replication timing (Supplementary Methods Tables 1-3).
In all cases, the same significant mutation types (and the same effect sizes) stand
out; in other words, the results are the same, regardless of the approach. The reason
is likely that the reference compartment is always sufficiently large for sampling error
to be small.
43
1.7.5 Comparing the X chromosome and autosomes:
additional considerations
In comparing compartments on the X chromosome and autosomes, we excluded the
pseudo-autosomal region unless otherwise specified, since sex-specific properties differ
between the PAR and the rest of the X chromosome. We considered additional
population-level properties that may affect the mutation spectrum differently for
the X and autosomes. In accordance with our prior expectation that biased gene
conversion should have a negligible effect on variants at very low frequencies, we
note no clear patterns of X-autosome differences for mutation types that are subject
to biased gene conversion. Similarly, because so many variants in the sample are
rare and thus young, we expect very little effect of either direct or linked selection
on the mutation spectrum a priori. Thus, we interpret these mutation patterns as
reflecting real and largely neutral differences between X and autosomes. We also
checked for differences in genotyping error rates between the X chromosome and
autosomes. Because the variant quality (QUAL) variable in the dataset is jointly
calculated based on males and females in the sample, the reported quality of variants
on the X chromosome is expected to be slightly lower. Nevertheless, the distribution of
variant quality is almost identical for the X chromosome and autosome (Figure 1.11),
and any small differences are likely further lessened because we used only the female
subset of the data. To rule out a potential interaction of error rate by mutation type
and compartment, we compared the genotype qualities and read depths for C>G and
C>A mutation types in compartments across which we found the distribution of these
44
types to differ. The average genotype quality and read depth is high for all mutation
types, and while there may potentially be small differences in error rates between
different types of mutation, these do not seem to differ across compartments in ways
that would affect our inference. For instance, average genotype quality and read depth
for C>G mutations is similarly distributed to all other mutation types combined both
in the PAR and Autosomes, while a strong enrichment of these types is seen only in
the PAR. We similarly did not observe a notable interaction of C>A quality metrics
with early and late replicating compartments; these cases are illustrated in Figure
1.12. We further replicated our analysis using two datasets (Uk10k and SGDP)
(The UK10K Consortium, 2015; Mallick et al., 2016) sequenced independently, with
varying levels of coverage (Figure 1.10). In order to validate signals observed in the
gnomAD data, we conducted a similar analysis using publicly available data from
the Simons Genome Diversity Project (SGDP) [117]. We considered only individuals
with ID beginning with “S” (as this subset was sequenced PCR-free and processed
using a consistent approach) and used filter level 1 (recommended as optimal for SNP
discovery in Mallick et al. 2016) to obtain a variant set of high quality. The SGDP
variants were polarized with respect to the major allele in the full SGDP sample of
“S” individuals. We limited our analysis to female individuals (100/256 individuals in
the dataset). Individual-level alternate allele counts at each variant position, reported
as 0, 1 (heterozygous), or 2 (homozygous), were summed over the 100 individuals to
obtain allele counts in the sample; no multi-allelic sites were seen in this sample.
Sites with >50% missing data were excluded. The major allele in the SGDP dataset
is 99% correlated with the gnomAD major allele when only variants at matched
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positions are considered. To estimate the mutational opportunities for each type of
site in this dataset, we combined accessible regions from 11 individuals (five with
predominantly European and six with African ancestry) and used the hg19 reference
to obtain trinucleotide context. We also replicated our analysis using variants in the
ALSPAC and TwinsUK subsets of the UK10K dataset (The UK10K Consortium,
2015). We limited our analysis to the 2,793 females. We polarized to the major
allele in the UK10K sample, and applied quality thresholds similar to those in the
gnomAD analysis. We excluded multi-allelic sites from this sample. Since accessible
regions were unavailable for this dataset, we used the accessible regions obtained for
the SGDP dataset, obtained as described above.
1.7.6 Obtaining data for the distribution of genomic
features
To investigate the association of biochemical features with mutational patterns in
the germline, we would ideally consider the distribution of these features in germline
tissue. In cases where we were limited to data from somatic cell lines, where possible
we focused on genomic features that are known to have stable or broadly similar
distributions across tissues-types, as these are more likely to be comparable between
the soma and germline. We downloaded replication timing data from two sources:
data for LCL lines was obtained from Koren et al., 2012, and data for three human
embryonic stem cell lines (H1, H7, and H9), produced as part of the ENCODE project,
was downloaded from the UCSC browser. Replication timing data are reported as a
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standardized score with negative scores representing later replication. To check for
systematic differences in the observed distributions of replication timing between the
two studies, we also downloaded data for the cell line most similar to LCL available
from ENCODE (GM12878); for these cells, the distribution of replication timing was
almost identical to the LCL data from Koren et al., 2012, suggesting that differences in
the distributions of replication timing between the LCL and embryonic stem cell lines
are not due to methodological differences, and likely reflect real biological differences
between cell lines. For autosomes, average replication timing is largely consistent
across different cell lines, both at the chromosomal level and at the 1Mb scale (Figure
1.13) [27, 73]. Since methylation is expected to be highly variable across tissues and
may well differ substantially between the germline and soma, we used CpG islands as
a binary proxy for methylation: CpG islands are hypomethylated relative to the rest
of the genome, across tissue-types [74, 75]. We obtained the X-inactivation status
(“inactive”, “escape”, “variable”, “unknown”) of genic regions on the X chromosome
from Tukiainen et al. 2017; this consensus status for 683 genes on the X chromosome
is based on combined information from multiple sources and experimental approaches,
across tissue-types. To be consistent with the Tukiainen et al. 2017 study, we used
Gencode v19 coordinates and annotations for genic regions on the X chromosome and
autosomes. The small number of regions of overlap between genes that were classified
as both “escape” and “inactive” were excluded from the analysis. DMC1 ChIP-seq
signal intensity on the X chromosome and autosomes, measured in spermatocytes,
was obtained from Pratto et al., 2014. DMC1 hotspots were defined as 1 kb regions
around the midpoint of hotspots identified by Pratto et al., 2014. We used hotspots
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and signal intensity values for the “AA2” individual; using average intensities and
the union of hotspots from all four individuals with PRDM9 alleles A and B does not
alter our qualitative results. DMC1 hotspots were grouped as weak (DMC1 signal
intensity 1-50), intermediate (signal intensity 50-150), and strong (signal intensity
>150). Because the X chromosome has a disproportionate number of very strong
DMC1 hotspots, we chose these criteria to obtain similar average hotspot intensities
on the X chromosome and autosomes in the first three bins, with the outliers in
the fourth; varying these thresholds does not alter our qualitative conclusions. We
obtained the list of autosomal regions enriched for clustered C>G mutations from
Jónsson et al., 2017. Finally, we used the female standardized recombination map
[118] to define female hotspots on autosomes (following Kong et al. 2010, windows
with recombination rates greater than 10-fold the genome average were considered
hotspots; increasing this threshold does not alter our qualitative conclusions).
1.7.7 Testing the effect of replication timing and other
genomic features on the autosomal mutation spectrum
For autosomes, average replication timing is largely consistent across cell lines, both
at the chromosomal level and at the 1Mb scale (Figure 1.13) [27, 73]. We compared
the mutation spectrum in autosomal regions that are early or late replicating in
LCL (Fig. 2a) and H9-hESC (Figure 1.14) cell lines. Regions were defined as
early replicating if the replication timing score was greater than or equal to 0.5, and
late replicating if it was less than or equal to -0.5 (the results remain qualitatively
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unchanged if these thresholds are varied). We aggregated replication timing data per
1 Mb window and per chromosome (using the bedtools map function). While the
choice of scale is somewhat arbitrary, averaging replication timing on the 1 Mb scale
is relatively lossless (Figure 1.13), and this scale has been used in other studies of
replication timing [65, 27]. In each 1 Mb window, we obtained the enrichment of each
of six broad mutational classes (C>A, C>G, C>T, T>A, T>C, T>G) relative to
all mutation types, and relative to all windows taken together. We excluded a small
number of windows in which the total number of mutations was outside the range of
two standard deviations from the mean. For the chromosome level analysis, for each
autosome, we obtained the enrichment of each of the six broad mutational classes
relative to all mutation types, and relative to all other autosomes taken together.
Averaging replication timing on entire chromosomes is useful because it allows us to
place the effect of replication timing on the X chromosome in context. To assess the
impact of other genomic features, we compared the autosomal mutation spectrum
in regions that lie within and outside CpG islands, and regions that lie in regions
of clustered de novo mutations thought to be due to double-strand break damage
(Figure 1.16). We note that many genomic features are correlated. As one example,
hypomethylated CpG islands tend to colocalize with early replicating gene regulatory
regions; we consider the effect of this interaction on the mutation spectrum (Figure
1.15).
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1.7.8 Controlling for genomic features on the
X-chromosome
For the X chromosome, the average difference in replication timing between cell lines
is thought to reflect X-inactivation status, which differs by cellular genotype and
the level of differentiation, and can be heterogenous in a cell population [90, 27,
92, 73, 91]. For instance, the LCL line is a female (XX) cell line with one stably
inactivated X chromosome, consistent with the significantly later replication of the
X on average (Supplementary Figure 8). The H1 embryonic cell line is male (XY),
whereas the H7 line is XX but with two active X chromosomes, and in both these
cases the X replicates on average at the same time as autosomes (Figure 1.13).
We did not observe late replication on the X chromosome for the female H9 cell line
(Figure 1.13), which is thought to have one inactive X chromosome. The reason
may be that this particular line is derived from 5-day old female embryos: since
the pre-implantation embryo undergoes global demethylation and is hypomethylated
around day 5 post-fertilization [60, 59], we do not necessarily expect to see an effect
of X-inactivation in this cell line. Thus, we did not have data for human embryonic
stem cells where one X chromosome is stably inactive; however, the differences in X-
inactivation for human embryonic cells in various states of differentiation is consistent
with X-inactivation status changing over time in the germline, and on average lying
somewhere in between that observed in the LCL cell lines and the human embryonic
stem cell lines. More generally, these patterns support the notion that X-inactivation
and replication timing on the X chromosome are highly correlated. We controlled
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for X-inactivation on the transcribed X chromosome using the X-inactivation status.
Complementary to this approach, and to ensure that the observed impact of X-
inactivation was not an artifact of a potential mis-classification of genes in the active
and inactive categories, we controlled for replication timing on the X chromosome.
To match the average replication timing on the X and autosomes, we considered
regions on the X chromosome and autosomes that have replication timing scores of
greater than or equal to -0.5 and less than or equal to 0.5 in the LCL cell line (Figure
1.18). The total length of callable regions (in gnomAD) with this property is about
700 Mb on autosomes and 50 Mb on the X. On average, variants in these regions
on both the X and autosomes have a similar (approximately zero) mean score for
replication timing. In matching the mean, we implicitly assumed that the effects of
replication timing on the mutation spectrum were roughly linear (there are some non-
linear effects on the X chromosome in regions of extremely late replication timing).
Changing the threshold does not alter our qualitative results as long as the mean
replication timing on the X chromosome and autosomes is close. We also considered
shared mutational patterns in early and late replicating regions of the X relative
to autosomes (Figure 1.19). Since the mean replication timing on the X is -0.75,
we considered late replicating regions to be those with a replication timing score
< -1.25, and early replicating regions, > -0.25; changing these thresholds changes
the power of our comparison but not the qualitative results. We ignored effects of
differences in CpG methylation between the X and autosome since we excluded CpG
sites in the X-autosome comparison. We assumed that any additional small effects of
methylation at other sites were controlled for indirectly by controlling for replication
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timing and/or X-inactivation. For the pseudoautosomal compartment, we did not
control for genomic features, since it does not undergo inactivation and replicates
early and thus, the mutation spectrum in this compartment should not be affected
by these features. All annotation sources are listed in (Table 1.1).
1.8 Supplementary Tables and Figures
Figure 1.6: The enrichment of mutation types on the X chromosome, relative to autosomes,
for rare variants (allele counts 1-5) versus common variants (variants at frequency 1% or
greater) in the sample. This analysis excludes CpG sites and the pseudoautosomal region.
Diamonds represent mutation types that differ by 5% in their mean fold enrichment between
the two comparisons. The black diagonal represents the x=y line. For each estimate, the
95% confidence interval from a binomial test for X-enrichment among common and rare
variants, respectively, is represented by the grey horizontal and vertical bars.
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Figure 1.7: The enrichment of mutation types on the X chromosome, relative to autosomes,
using the major allele in the sample versus the ancestral allele from the human chimp
ancestral sequence. This analysis excludes CpG sites and multi-allelic sites. The black
diagonal represents the x=y line. For each estimate, the 95% confidence interval from a
binomial test for enrichment on the X chromosome relative to autosomes, using the major
allele or the human chimp ancestral allele, respectively, is represented by the grey horizontal
and vertical bars.
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Figure 1.8: The enrichment of mutation types on the X chromosome, relative to autosomes,
in all variants including multi-allelic sites, or bi-allelic sites only. Diamonds represent mu-
tation types that differ by 5% in their mean fold enrichment between the two comparisons.
The black diagonal represents the x=y line. For each estimate, the 95% confidence interval
from a binomial test for enrichment on the X chromosome relative to autosomes, using all
sites or only bi-allelic sites, respectively, is represented by the grey horizontal and vertical
bars.
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Figure 1.9: The effect of forward variable selection and excluding CpG sites on the X-
autosome comparison. The black diagonal represents the x=y line. For each estimate, the
95% binomial confidence intervals are represented by the grey horizontal and vertical bars.
(a) The enrichment of mutation types on the X chromosome, relative to autosomes, when
all 96 types are considered, versus when CpG sites are excluded. (b) The enrichment of
mutation types on the X chromosome, relative to autosomes, with and without the forward
variable selection procedure (see Supplementary Methods).
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Figure 1.10: Comparison of the X-Autosome mutation spectrum in gnomAD with the
UK10K and SGDP datasets. The gnomAD dataset was down-sampled to match the com-
parison dataset in each case. These analyses exclude CpG sites and multi-allelic sites. The
black diagonal represents the x=y line. For each estimate, the 95% confidence interval
from a binomial test for X-enrichment relative to autosomes in gnomAD and the UK10K
or SGDP datasets, respectively, is represented by the grey horizontal and vertical bars. (a)
The enrichment of mutation types on the X chromosome, relative to autosomes, in gnomAD
versus UK10K. (b) The enrichment of mutation types on the X chromosome, relative to
autosomes, in gnomAD versus SGDP.
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Figure 1.11: (a) Distribution of Variant Quality on the X chromosome and Autosomes
(b) Distribution of Variant Quality on the X chromosome and Autosomes by frequency
bin. Note that this reported measure of variant quality is based on the full sample with
males and females and might be expected to be slightly lower on the X chromosome (see
Supplementary Methods)
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Figure 1.12: Average genotype quality and read depth by mutation type and compartment.
Note that these reported measures of variant quality are based on the full sample with
males and females and might be expected to be slightly lower on the X chromosome. (a)
Genotype quality for C>A mutations types in X-Autosome compartments with differences
in replication timing, and for C>G versus all other mutation types in the PAR and other
relevant X-Autosome compartments. (b) Read Depth for C>A mutations types in X-
Autosome compartments with differences in replication timing, and for C>G versus all
other mutation types in the PAR and other relevant X-Autosome compartments.
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Figure 1.13: Variation in replication timing scores by cell type. Positive values indicate
early replication. (a) The distribution of replication timing scores for LCL and human
embryonic stem cell lines (hESC1, hESC7, hESC9). The X chromosome is shaded in red.
The average scores on autosomes and on the X are denoted by the red and black vertical
lines, respectively. (b) Mean replication timing for 1 Mb windows for the LCL and hESC9
cell types. Autosomal windows are shown in grey; windows on the X chromosome have been
overlaid in black. (c) Fine scale replication timing for chromosomes 1 and X. Grey points
reflect raw replication timing data in bins of approximately 100 bp. The dashed red lines
reflect averages over 1 Mb windows. The horizontal black line indicates the chromosome-
level mean replication timing. (d) Mean replication timing at the chromosomal level for the
LCL and hESC9 cell types.
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Figure 1.14: The effect of replication timing on the mutation spectrum using the hESC9 cell
type. (a) Comparison of the spectrum of 96 mutation types in late replicating autosomal
regions relative to early replicating autosomal regions. Only significant differences are
shown. Positive and negative effects are ranked separately in order of effect size from left
to right. Late replicating regions are defined as having a replication timing score <= -0.5
and early >= 0.5. (b) The relative enrichment of six mutational classes in 1Mb windows
relative to all autosomal windows combined, ordered by the mean replication timing in 1Mb
windows. Positive x-values indicate early replication. Windows on autosomes are shown in
solid grey circles; windows on the X chromosome have been overlaid in black open circles.
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Figure 1.15: The effects of methylation and replication timing on the mutation spectrum.
Only significant differences are shown. Positive and negative effects are ranked separately
in order of effect size from left to right. CpG islands are used as a proxy for regions of
hypomethylation. Late replicating regions are defined as having a replication timing score
<= -0.5 and early >= 0.5. (a) Comparison of the mutation spectrum at CpG sites in
late versus early replicating regions outside CpG islands. (b) Comparison of the mutation
spectrum at non-CpG sites in late versus early replicating regions outside CpG islands. (c)
Comparison of the mutation spectrum at CpG sites in late versus early replicating regions
inside CpG islands. (d) Comparison of the mutation spectrum at non-CpG sites in late
versus early replicating regions inside CpG islands.
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Figure 1.16: The effect of biochemical features on the mutation spectrum. (a) Comparison
of the spectrum of 96 mutation types in autosomal regions in CpG islands relative to
autosomal regions outside CpG islands. Positive and negative effects are ranked separately
in order of effect size from left to right; only the top 50 significant positive and negative
effects are shown for legibility. The size of the circle reflects the number of mutations of
that type. CpG transitions are labeled in dark red. (b) Comparison of the spectrum of
96 mutation types in autosomal regions identified as rich in clustered de novo mutations
(cDNMs) by Jónsson et al., 2017, relative to other autosomal regions. Only significant
differences are shown. Positive and negative effects are ranked separately in order of effect
size from left to right. The size of the circle reflects the number of mutations of that type.
(c) Variation in the mutation spectrum for individual chromosomes. The enrichment level
is shown for individual autosomes relative to all other autosomes combined and, on the X,
relative to all autosomes combined; each point reflects one of 16 trinucleotide contexts for
a particular mutational class. CpG transitions are labeled in dark red.
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Figure 1.17: The mutation spectrum in the active and inactive genic regions of the X
chromosome relative to genic regions in autosomes. These X-Autosome comparisons exclude
all CpG sites and the pseudoautosomal region (PAR). (a) The spectrum of six mutational
classes in the active genic regions of the X chromosome relative to autosomes (in red),
compared to known male female differences from Jónsson et al., 2017 (in black). Solid
points are statistically significant differences at the 5% level, accounting for multiple tests.
(b) The X-Autosome mutation spectrum in inactive genic regions of the X relative to
autosomes (in red) compared to known male female differences from Jónsson et al., 2017
(in black). Solid points are statistically significant differences at the 5% level, accounting
for multiple tests.
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Figure 1.18: The mutation spectrum on the X chromosomes and autosomes with and with-
out matching for average replication timing. These X-Autosome comparisons exclude all
CpG sites and the pseudoautosomal region (PAR). The distribution of replication timing
for the X and autosomes is shown in the right panels, with the mean replication timing on
the X and autosomes represented by dashed vertical black lines. (a) The X-Autosome mu-
tation spectrum (in red), unadjusted for replication timing differences, compared to known
male female differences from Jónsson et al., 2017 (in black). Solid points are statistically
significant differences at the 5% level, accounting for multiple tests. (b) The X-Autosome
mutation spectrum of the X and autosome matched for average replication timing, in red,
compared to known male female differences from Jónsson et al., 2017 (in black). Solid
points are statistically significant differences at the 5% level, accounting for multiple tests.
Note that the left panel is a duplicate of Fig. 4b, to enable a direct comparison between the
results with and without matching for replication timing. The shaded regions in the right
panel indicate the range of replication timing (between -0.5 and 0.5) used in this analysis.
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Figure 1.19: Comparison of the mutation spectrum in early and late replicating compart-
ments of the X chromosome versus autosomes. The pseudoautosomal region (PAR) and
CpG sites are excluded from this analysis. Only significant differences are shown. Positive
and negative effects are ranked separately in order of effect size from left to right. The
size of the marker reflects the number of mutations of that type. Hollow circles indicate
the three mutation types that are significantly different in both early and late replicating
compartments of the X relative to autosomes and also found to be significant differences in
both the escaped and inactive compartments of the X relative to autosomes. Crosses denote
mutation types reported as significant sex differences by Jónsson et al., 2017. Hollow dia-
monds represent other mutation types that are significantly different in both early and late
replicating compartments of the X relative to autosomes. The distribution of replication
timing for the X and autosomes is shown in the right panels, with the mean replication
timing on the X and autosomes represented by dashed vertical black lines. Shaded regions
indicate the range of replication timing used in the corresponding analysis. (a) Enrichment
of mutation types in early replicating regions of the X chromosome (replication timing score
> -0.25) relative to autosomes. (b) Enrichment of mutation types in late replicating regions
of the X chromosome (replication timing score < -1.25), relative to autosomes.
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Figure 1.20: Comparison of the mutation spectrum in regions identified as recombination
hotspots, relative to autosomal non-hotspots. These analyses exclude regions on autosomes
rich in clustered de novo mutations, identified by Jónsson et al., 2017. CpG sites are ex-
cluded. Only significant differences are shown. Positive and negative effects are ranked
separately in order of effect size from left to right. The size of the circle reflects the num-
ber of mutations of that type. (a) The mutation spectrum in hotspots of DMC1-binding
measured on autosomes in males, defined as autosomal regions with hotspot intensity > 0.
(b) The mutation spectrum in female crossover hotspots, defined as regions with standard-
ized recombination rate > 10. (c) The mutation spectrum in hotspots of DMC1-binding
measured on the X chromosome in males, defined as regions outside the PAR with hotspot
intensity > 0.
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Table 1.1: Sources of whole genome annotation data.
Variants




UK10K ALSPAC and TwinsUK (https://www.uk10k.
org/data_access.html)
Genomic features











DMC1 ChIP-seq Human spermatocytes (GEO Accession GSE59836)
http://www.ncbi.nlm.nih.gov/geo/
Recombination rate Standardized female recombination maps (https:
//www.decode.com/addendum/)
Clustered DNM regions Supplementary Table 12 (https://www.nature.
com/articles/nature24018)
Genic regions Gencode v19 genes (ftp://ftp.ebi.ac.uk/pub/
databases/gencode/Gencode_human/release_
19/gencode.v19.annotation.gtf.gz)
Genic regions of X-
inactivation and escape







Mutation saturation for fitness
effects at human CpG sites
2.1 Abstract
Whole exome sequences are now available for hundreds of thousands of humans. For
highly mutable sites, that means we are approaching an important limit, in which
datasets are large enough that, in the absence of natural selection, every site will
have experienced at least one mutation in the genealogical history of the sample.
Indeed, methylated CpG sites that mutate to T at an elevated rate (~10-7 per bp per
generation) are already very close to meeting that criterion: In a sample of 390,000
individuals, 99% of putatively-neutral, synonymous CpG sites harbor a C/T poly-
morphism. CpG sites therefore provide a natural mutation saturation experiment for
fitness consequences: as we show, at current sample sizes, not seeing a polymorphism
is indicative of strong selection against that mutation. We leverage this idea in order
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to identify CpG transitions that are too deleterious to segregate in current samples
across annotations with similar mutation rates. On that basis, we estimate that
whereas ~27% of loss of function mutations are likely to be highly deleterious, only
6% of missense mutations are; however, the proportion increases substantially--up to
21%--depending on the type of functional site in which they occur. As we discuss, in
contrast to CpG transitions, mutation types with rates on the order of 10-8 or 10-9
remain very far from saturation.
2.2 Main text
A long-standing aim of population genetics has been to model the impact of selection
on variation within and between species, and to infer fitness effects of mutations from
patterns of genetic variation [1, 7, 2, 3, 4]. Because purifying selection depletes dele-
terious variation over time, it leaves a footprint of conservation in DNA sequences.
This signal of reduced genetic variation can then help pinpoint genomic loci of func-
tional importance: for instance, comparisons of sequences across species have been
widely used to identify relatively invariant regions, presumably maintained by strong
selection over millions of years because of their functional importance [12, 16, 15].
The same general approach is also a useful tool in human genetics, given that genomic
sites under purifying selection are enriched for sources of genetic disease and other
traits of interest [12, 13, 14, 16, 17]
When using genetic variation within humans to identify sites under selection,
the time scale over which mutations may have accumulated is relatively short. The
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miniscule mutation rate at a typical site in the genome (~10-8 mutations per gener-
ation) therefore poses a major difficulty: even sites at which changes have no effect
on fitness may not be segregating in available samples. A site could be monomorphic
when mutations at that site have no fitness consequences at all or, at the other ex-
treme, when the mutations are embryonically lethal. Consequently, in small samples
of a few hundred or even thousands of individuals, with only a small proportion of
sites segregating, there is little information on the distribution of fitness effects across
the genome. The lack of information about most sites also limits the utility of such
samples in distinguishing benign from pathogenic variants in a clinical context.
In part to overcome these limitations, public repositories of human exome se-
quences have now grown to include data from hundreds of thousands of individuals
[119, 13, 14, 120, 121]. In principle then, we should for the first time have at least
some direct information about the strength of selection on an unprecedented number
of sites in the human genome--particularly at the subset of sites with higher than
average mutation rates [13]. To evaluate the merits of this notion, we considered
CpG sites methylated in the germline, since these experience mutations much more
frequently than any other type of site [23, 20, 21]. We focus on “highly-methylated”
CpG sites in exons, defined as those that are methylated >=70% of the time in both
testes and ovaries. For these ~1.1 million sites (of 1.8 million total CpG sites in se-
quenced exons), we calculate a mean haploid C>T mutation rate of 1.17×10-7 using
de novo mutations (Methods, Figures 2.5 - 2.6), an order of magnitude more than
the genome average [21].
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Figure 2.1: Fraction of highly methylated CpG sites that are polymorphic for a transition,
for each sample. The combined dataset encompasses three non-overlapping data sources:
gnomAD (v2.1), the UK Biobank (UKB), and the DiscovEHR cohort. “European” sam-
ples include the “Non-Finnish European” subsets of exome and whole genome datasets in
gnomAD, as well as the UK Biobank and DiscovEHR, which have >90% samples labeled
as of European ancestry.
Next, we collate polymorphism data made public by gnomAD [13], the UK
Biobank [120], and the DiscovEHR collaboration between the Regeneron Genetics
Center and Geisinger Health System [119] to ascertain whether a site is segregating
in a sample of ~390,000 individuals (Methods). To focus on the subset of genic
changes most likely to be neutrally-evolving, we consider the subset of ~350,000
highly-methylated CpG sites at which C>T mutations do not change the amino
acid. At these sites, 94.7% of all possible synonymous CpG transitions are observed
in the gnomAD data alone, and 98.8% in the combined sample including all three
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datasets (Figure 2.1).These data indicate that transitions are very close to saturated
at highly methylated CpG sites in the sample of 390,000 individuals--in other words,
nearly every highly methylated CpG site where a mutation to T is putatively neutral
has experienced at least one such mutation in the history of the sample.
If we assume that in the absence of selection, almost every highly methylated CpG
site would be segregating a T at current sample sizes, then not seeing a T strongly
suggests that it was removed by selection. How strong selection has to be for the site
to be monomorphic is unclear, however. Because genetic variation arises from the
combined influences of mutation, selection, and random genetic drift over evolutionary
time, and because selection strengths and mutation rates vary across genomic loci,
isolating the effects of selection requires assumptions about demographic history and
the mutation rate at the locus of interest. To examine the relationship between
selection and the amount of variation at a locus, we simulate evolution at a single
CpG site that undergoes mutations to T at rate 1.2×10-7 per generation, under a
variant of the widely-used Schiffels-Durbin demographic model for population growth
in Europe [9], in which we set the effective population size Ne equal to 10 million
for the past 50 generations (Methods). While this model is a vast oversimplification,
it mimics the qualitative behavior under neutrality. For instance, in a sample size
of 780,000 chromosomes, it suggests that a site experiences at least one mutation in
99% of simulations (Figure 2.2). Thus, 99% of neutral sites with this mutation rate
are expected to be polymorphic at this sample size, in good agreement with what
we observe in data for synonymous CpG transitions (Figure 2.1). As expected,
the probability that a site is segregating is lower if it is under selection than if it is
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neutral; this effect is particularly pronounced for strong selection in smaller sample
sizes (Figure 2.2).
Although the relationship of selection strengths to clinical pathogenicity is not
straight-forward, selection coefficients on the order of 10-2 or 10-3 are likely to be of
relevance to determinations of pathogenicity in clinical settings ([122, 123]; Agarwal,
Fuller, Przeworski, in prep.). For instance, many mutations with hs on the order
of 10-3 may substantially increase liability to a disease; others may on their own be
highly deleterious to some individuals that carry them, enough to produce clinically
visible effects, but vary substantially in their penetrance. Importantly then, even such
highly deleterious mutations are expected to segregate in large samples: in current
exome sample sizes, a site with a heterozygote selection coefficient (hs) of 0.5×10-3 is
almost always observed segregating (Figure 2.2A). This follows from the expectation
under mutation-selection-drift balance: for example, in a constant population size,
a mutation that arises at rate 1.2×10-7 per generation and is removed by selection
at rate 0.05% per generation is expected in the population at frequency 2.4×10-4 on
average; in a sample of 780k, the mean number of copies is 187. Thus, even with
substantial variation due to genetic drift and sampling error, such a site should almost
always be segregating at that sample size. In fact, even a mutation with hs of 5%
would quite often be observed. An implication is that, although reference repositories
such as gnomAD were partly motivated by the possibility of excluding deleterious
variants--with the idea that seeing a variant of unknown function in a reference data
set is suggestive that the variant is benign--as samples grow in size, it cannot simply
be assumed that deleterious variants are absent from reference datasets. Indeed, with
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sufficiently large sample sizes, the only variants ultimately not observed will be those
that are embryonic lethal.
Conversely, without information on the mutation rate and sample size, the ob-
servation that a site is segregating in a sample only excludes the possibility that the
variant is embryonic lethal. In other words, an assessment of the fitness consequences
of a site, whether or not segregating, can only be made given a mutation rate and
sample size. Moreover, the information content associated with what is segregating or
not shifts with sample size. To make this point more concrete, we assume a relatively
uninformative log-uniform prior on the selection coefficient s ranging from 10-7 to 1
and fix the dominance coefficient h=0.5 (as for semi-dominant mutations, only the
compound parameter hs affects allele dynamics; reviewed in [124]). We then estimate
the posterior distribution of hs at a site conditional on a mutation rate of 1.2x10-7
per site per generation and the demographic model described above, given that the
site is monomorphic, segregating with 10 or fewer derived copies of the T allele, or
segregating with more than 10 copies (Figure 2.2, Methods). It is worth noting
here that at current sample sizes, the amount of information per site is limited and
thus the choice of prior can be consequential (Figure 2.7). Given this sensitivity
to priors, and because our demographic model is a clear over-simplification, we do
not infer parameters but instead use the model to understand qualitative trends by
sample size.
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Figure 2.2: (a) Probability of a CpG site segregating in simulations, if the mutation has
no fitness effects (hs=0) and if it is deleterious (with a heterozygote selection coefficient
hs=0.05%) or highly deleterious (with a heterozygote selection coefficient hs=5%, where s
is the selection coefficient and h is set to 0.5). (b) Prior and Posterior log densities for hs
for a mutation observed at 0, 1-10, or >10 copies at various sample sizes. (c) Bayes odds
(i.e., posterior odds divided by prior odds) of s > 0.001 for a mutation observed at 0, 1-10,
or >10 copies, at various sample sizes.
At very small sample sizes, most sites are monomorphic, and there is not much
information at these sites (i.e., being monomorphic is consistent with both neutrality
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and very strong selection). For the small subset of sites that is segregating, the
mutation is unlikely to be highly deleterious (and cannot be embryonic lethal): for
instance, the posterior odds that a site segregating at 10 or more copies in a sample
of 10,000 is under strong selection are 10-fold lower than the prior odds (Figure
2.2C). In short, there is almost no information about the overall distribution of
fitness effects across sites. In contrast, with larger samples sizes, in which putatively
neutral CpG sites reach saturation (~780k; such that that their being invariant by
chance is unlikely), the posterior distribution for invariant sites is highly peaked:
what is not segregating is likely strongly deleterious. Given our assumptions, the
odds that an invariant site in a sample of 780k is under strong selection (set as hs
> 5×10-4) are ~10-fold greater than those for sites segregating even at relatively low
frequencies.
Somewhat counter-intuitively, with increasing sample sizes, the average polymor-
phic site becomes consistent with a larger range of selection coefficients, as sites that
are under even strong selection start segregating. Thus, the observation that a site
is segregating in a large sample is actually less informative about selection than in
a small sample, while the opposite is true for invariant sites. Finally, at even larger
sample sizes on the order of a few million chromosomes, once neutral and deleterious
mutations are potentially present at multiple copies, it becomes possible to distinguish
between strongly and weakly selected segregating sites by comparing the frequencies
at which they are observed (given an accurate demographic history for the sample).
These considerations underscore that interpreting variants of unknown function by
reference to repositories such as gnomAD, let alone to disease cohorts that are likely
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enriched for deleterious variation (e.g., [125]), become much more complicated in the
absence of an underlying model.
In that regard, we note that thus far we have implicitly assumed the same muta-
tion rate at all CpG sites highly methylated in the germline, but this is unlikely to be
strictly true, since local sequence context and broader epigenetic features influence
local mutation rates [34, 65]. An advantage of conditioning on highly methylated
CpG sites is that there is a single known mechanism, i.e., spontaneous deamination
of methyl-cytosine, that is believed to be predominantly responsible for their uniquely
high mutability [23]. For instance, although regions in and outside exons differ con-
siderably in epigenetic features, replication timing, and the impact of transcription
associated damage and repair, there is no appreciable difference in average de novo
mutation rates at methylated CpGs inside and outside exons (FET p-value = 0.08,
Figure 2.8). Thus, while there is likely some residual variation in mutability per
site, it is expected to be small relative to the mean mutation rate. At current sample
sizes, a small amount of mutation rate variation would be expected to slightly reduce
the fraction of synonymous sites saturated, and if not modeled, may be misconstrued
as purifying selection at individual sites that are less mutable (Figure 2.9).
Given the lack of knowledge of mutation rates at each site and uncertainty
about the appropriate demographic model, we cannot infer hs reliably for any given
monomorphic CpG site. Instead, we compare the typical fitness effects of CpG tran-
sitions across annotations. For this entirely empirical approach, we only need the
distribution of mutation rates to be the same across annotation classes and to as-
sume that the distribution of genealogical histories is the same, i.e., that the classes
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are subject to comparable effects of linked selection. We therefore verify that the
mean de novo mutation rate is the same for synonymous sites as for other annota-
tions (Figure 2.3). We also check that the rate at which two DNMs occur at the
same site, a summary statistic that reflects the variance in mutation rates, is not
significantly different for methylated CpGs inside and outside exons (FET p-value
= 0.5; Figure 2.8). While the distribution of mutation rates could nonetheless dif-
fer somewhat, these observations suggest that the assumption of similar transition
rates at highly methylated CpGs across annotations is warranted. The assumption
of similar distributions of genealogical history also seems sensible, given that the an-
notations are closely interdigitated within genic regions; nonetheless, we also check
that each comparison yields similar results if the annotations are matched for the
predicted effects of linked selection ([126]; see below).
First, we consider the fraction of CpG sites segregating for a transition in each
annotation class in a sample of 780k chromosomes, normalized to what is seen at syn-
onymous sites. All categories of missense, loss-of-function, and regulatory variants
show a significant depletion in the fraction of segregating sites compared to synony-
mous variants (Figure 2.3). Moreover, the degree of depletion is directly informative
about the fraction of sites under selection in each of the annotation classes.
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Figure 2.3: (a) DNM rates for CpG transitions at highly methylated sites by annotation
class, normalized by the total DNM rate in exons (b) Fraction of highly methylated CpG
sites that are segregating as a C/T polymorphism in an annotation class, relative to the
fraction of synonymous sites segregating. Error bars are 95% confidence intervals assuming
the number of segregating sites is binomially distributed (Methods). LOF variants are
defined as stop-gained and splice donor/acceptor variants that do not fall near the end of the
transcript, and meet the other criteria to be classified as “high-confidence” loss-of-function in
the gnomAD data. (c) The number of opportunities for synonymous and missense changes
involving highly methylated CpG transitions by the type of functional protein site. (d)
The proportion of synonymous and missense segregating C/T polymorphisms in different
classes of functional sites. All annotations are obtained using the canonical transcripts of
protein coding genes (see Methods).
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Notably, these data suggest that there are ~27% fewer loss-of-function variants
than would be expected under neutrality. With our model and our relatively uninfor-
mative prior, an invariant site in this sample of 390,000 individuals is very likely to
have an hs > 0.5×1e-3 (posterior odds ~11.5 to 1, Figure 2.2). If we assume that all
true LOF mutations in a gene (after filtering for those at the end of transcripts, for
instance) are identical in their fitness cost, as is standard (e.g., [122, 13]), then CpG
LOF mutations should be informative about the general distribution of consequences
for LOF mutations. Supporting the assumption that true LOF mutations within a
gene are exchangeable, when we compare the set of CpG sites at which mutations lead
to possible protein-truncation in the first and second half of transcripts respectively,
approximately the same number are under strong selection in both subsets (Figure
2.10; FET p-value ~0.09).
In contrast, only 6% of missense variants and splice region variants appear to
be under the same degree of selection (whether or not we match for the effects of
linked selection; see Figure 2.11). While LOF and missense annotation classes
are most commonly used in determinations of variant pathogenicity, any two sets
of highly methylated CpGs with similarly-distributed mutation rates can be ranked.
We therefore consider the fitness effects of missense mutations, stratifying them by
the type of functional site in which they occur. Strikingly, for the subset of sites at
which missense mutations may disrupt or alter binding, particularly DNA-binding,
~21% of variants are likely to be under strong selection, in contrast, say, to missense
changes within trans-membrane regions (Figures 2.3, 2.12, 2.11). Thus, a more
fine-grained classification of missense mutations reveals strong selection acting on a
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subset--on par with what is seen for LOF mutations.
Another common approach is to group sites by conservation scores or measures
derived from conservation scores such as CADD [127]. As expected, the fraction of
sites segregating decreases with increasing CADD scores, with 17% of highly methy-
lated CpG sites monomorphic for the top decile of CADD scores (Figure 2.13) We
note that for these CpG sites, mean mutation rates are similar across CADD deciles,
as expected if DNMs are rarely embryonic lethal, and if there is limited variation
within this set. Importantly, however, this is no longer the case when considering
all CpG sites in exons: for this larger set of sites, the mean de novo mutation rate
varies across deciles of CADD, potentially because these scores, while meant to iso-
late the effects of selection, nonetheless confound mutation rates and conservation
to some extent (Figure 2.13). We therefore caution that included among relatively
high CADD scores in the genome are likely some sites that are not in fact unusually
constrained, but have a lower mutation rate.
Given that current exome samples are informative about selection at highly
methylated CpGs, a natural question is to ask to what extent there is also infor-
mation for less mutable types, with mutation rates on the order of 10-8 or 10-9. That
synonymous CpG sites are close to saturation when they experience mutations to T
at a rate of of 1.17×10-7 per generation implies that, on average, the total branch
length of the genealogy relating the 390K individuals is at least 0.85x107 generations
(i.e., at a site, the sum of the branch lengths of the genealogy is on average greater
than 1 divided by 1.17×10-7). Assuming the average length of the genealogy is com-
parable or shorter for other types of sites (Figure 2.14), we should therefore expect
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that most sites with much lower mutation rates are not segregating. Indeed, for sites
with mutation rate on the order of 10-9, which is the case for the vast majority of
non-CpGs, the fraction of possible synonymous T>A variants observed is ~4% in the
sample of 780K chromosomes, compared to 99% for C>T variants at highly methy-
lated CpGs and ~30% for all other C>T variants (Figure 2.4). Thus, at current
sample sizes, there is not much information about selection for these mutations. One
implication is that the genealogical history of this sample is over 0.85x107 generations
long, but substantially shorter than 108 generations.
Figure 2.4: (a) Fraction of possible synonymous C>T mutations with high levels of methy-
lation in the germline, other C>T mutations, and the fraction of possible synonymous T>A
mutations that are observed in a sample of given size. (b) Probability of a polymorphism
in simulations, assuming neutrality, a specific demographic model and a given mutation
rate (see Methods).
Since the length of the genealogy does not increase linearly with the number of
samples, as is well appreciated from coalescent theory [5], saturation may not even
be achievable in extremely large samples on the order of tens of millions for such
mutation types. Under our choice of demographic model and assuming neutrality, a
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sample of 780,000 chromosomes has a genealogy spanning an average of 40 million
generations. Increasing the number of samples by a factor of 12 only increases tree
length ~3.3x (Figure 2.4, Figure 2.15); thus, a site that mutates at rate 10-9 per
generation is expected to have experienced ~0.04 mutations in the genealogical history
of a sample of ~1 million, and 0.1 mutations in a sample of 10 million. For most types,
therefore, mutation saturation is far off, and information on selection is limited to
the few sites that are segregating in current samples (Figure 2.4, Figure 2.16).
Quantitative predictions of our model are unreliable, given uncertainty about
the demographic history and in particular the recent effective population size in
humans (Figure 2.15) Moreover, for simplicity, we model one or at most two pop-
ulations, when mixed ancestry samples have slightly longer genealogical histories
(Figure 2.15). Thus, as samples diversify by ancestry, we will capture slightly more
variation than if we only include individuals from similar ancestries. We also note
that for the very large sample sizes considered here, the multiple merger coalescent
is the more appropriate model [128]. Nonetheless, the qualitative statement that less
mutable types remain very far from saturation will hold in the foreseeable future.
In this light then, it is of interest to ask whether the distribution of fitness effects
at CpG sites provides a reasonably good approximation for what we might expect to
see at other types of sites in the exome. In comparison to other types of sites, CpGs
are somewhat enriched for synonymous sites and depleted for missense sites compared
to other mutation types and the distribution of CADD scores slightly (though given
the amount of data, highly significantly) skewed towards lower values (KS test p-value
<< 10-5; Figure 2.17), as perhaps expected from the behavior of CADD scores in the
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presence of mutation rate variation. These differences are subtle, however, suggesting
that the distribution of fitness effects at highly mutable CpG sites is a useful proxy
for what to expect for the rest of the exome.
Previous work on inferring this distribution in humans and other organisms relied
on very small sample sizes and thus was forced to assume a specific and arbitrary
parametric form, inferred with very little or no information about moderately or
strongly selected sites [129, 130, 131]. By leveraging the vast exomic data sets now
assembled for humans, it is possible to access these questions much more directly, in
order to both identify specific sites likely to be under strong selection and quantify the
fraction of highly deleterious mutations across annotations. There is still not enough
information to precisely estimate the strength of selection at individual sites in the
genome, however. For methylated CpG sites, which have a mutation rate of 10-7,
this should become possible with samples of a few million individuals. Determining
the distribution of selection coefficients in the human genome is therefore within
reach, at least through the lens of CpG sites and provided a good characterization
of mutation rate variation within this class. More generally, better predictions of
mutation rates from de novo mutation data or models that rely on our increasing
understanding of mutational mechanisms should enable inferences about fitness effects
in other mutational contexts.
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2.4 Materials and Methods
2.4.1 Processing de novo mutation data
We obtained ~190,000 published de novo mutations in a sample of 2976 parent-
offspring trios that were whole genome sequenced [26]. To date, this is the largest
publicly available set of trios that, to our knowledge, have not been sampled on the
basis of a disease phenotype. Unless otherwise specified, we use these DNMs to calcu-
late mutation rates, as described in later sections. We converted hg38 coordinates to
hg19 coordinates using UCSC Liftover. We excluded indels, and all DNMs that occur
outside the ~2.8 billion sites covered by gnomAD v2.1.1 whole genome sequences. We
obtained the immediately adjacent 5’ and 3’ bases at each position from the hg19 ref-
erence genome, so that we had each de novo mutation within its trinucleotide context;
we used this information to identify CpG sites. Where such data were available (for
89% of CpG de novo mutations), we also annotated each site with its methylation
status in testes and ovaries (see Table 2.1).
85
2.4.2 Processing polymorphism data
We downloaded publicly available polymorphism data from gnomAD [13], the UK
Biobank [120], the DiscovEHR collaboration between the Regeneron Genetics Center
and Geisinger Health System [119], and 1000 Genomes Phase 3 [71]. Where needed,
we lifted over coordinates to the hg19 reference assembly using the UCSC LiftOver
tool. Salient characteristics of these samples are summarized below.
For the gnomAD data, we obtained the allele frequency for each variant in the full
exome and genome samples, as well as their Non-Finnish European (“NFE”) subsets
from the VCF files (in hg19 coordinates) provided. For each sample, we obtained
the set of segregating sites (i.e., the set of variants that pass gnomAD quality filters
and have an allele frequency > 0 in the sample). For the 1000 Genomes Phase-3
data, we similarly obtained the set of variant positions. Note that the 1000 Genomes
samples are also contained within the gnomAD sample. For the DiscovEHR sample,
allele frequencies are available where MAF > 0.001 (and set equal to 0.001 for lower
values>0); this information allows us to determine the set of sites segregating in this
sample, but we do not have access to any other information about individual variants.
Additional processing was required for the UK Biobank exome sequencing data.
We downloaded the population-level plink files with exome-wide genotype information
for ~200,000 individuals. We excluded exome samples that did not pass variant
or sample quality control criteria in the previously released genotyping array data.
Specifically, we excluded samples that have a discrepancy between reported sex and
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are outliers based on heterozygosity and missing rate, as detailed in Bycroft et al.,
2018 [132]. Finally, we excluded individuals who withdrew from the UK Biobank by
the end of 2020. This left us with 199,930 exome samples that overlap with the high-
quality subset of the genotyped samples. We additionally limited our analysis to the
list of ~40 million exonic sites with an average of 20x sequence coverage provided by
UK Biobank, and for which variants met the QC criteria described in Szustakowski
et al., 2020. We transformed the processed plink files into the standard variant call
format, polarized variants to the hg38 reference assembly, and obtained the frequency
of the non-reference allele in the sample. We then lifted over the coordinates from
hg38 to hg19 using the UCSC LiftOver tool. We excluded the few positions where
the reference alleles were mismatched or swapped between the two assemblies.
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2.4.3 Identifying and annotating mutational opportunities
in the exome
For all possible mutational opportunities in sequenced exons, we collated a variety
of functional annotations. To this end, we first generated a list of all possible SNV
mutational opportunities in the exome. We obtained the list of sites that fall in
exons or within 50bp of exons in Gencode v19 genes and that are among the ~2.8
billion sites covered by gnomAD v2.1.1 whole genome sequences. For each position,
we extracted the reference allele from the hg19 assembly and generated the three
possible single-nucleotide derived alleles. We also obtained the immediately adjacent
5’ and 3’ bases at each position from the hg19 reference genome, so that we had each
mutational opportunity within its trinucleotide context; we used this information to
identify CpG sites. Where such data were available, we also annotated each site with
its methylation status in testes and ovaries.
To identify sites at which variants or de novo mutations could be confidently
assayed by whole-exome sequencing methods, we obtained regions targeted in whole
exome sequencing from gnomAD and the UK Biobank. We limited our analysis
to sites that were covered at 20x or more in the exome sequencing subsets of both
gnomAD and UK Biobank (that lifted over correctly to the hg19 assembly), which
we refer to as ”accessible sites”.
We then annotated the ~90 million mutational opportunities (at 30 million sites)
with CADD scores and variant consequences using Variant effect predictor (v87,
Gencode V19) and the hg19 LOFTEE tool [13] to flag high-confidence (“HC”) loss-
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of-function variants. For loss-of-function variants, we also noted their location in the
gene by exon number (e.g., in exon 10 of 12 exons in the gene). We used a database
of curated protein features derived from Refseq proteins [133] to annotate all sites in
protein coding genes that were associated with a particular type of functional activity
(detailed functional annotations were available for 62,387 of 1.1 million highly methy-
lated CpG sites). At each site, we used either the primary ”site-type” annotation,
or when that was missing or listed as ”other”, we extracted the annotation from the
more detailed ”notes” field where this information was provided.
Because there are multiple transcripts for each variant, we limited our analysis
to the ”canonical” protein-coding transcript for each gene provided by Gencode to
obtain a single annotation for each variant. For 10-20% of variants this approach
still yielded multiple possible consequences per variant, for instance, where there
are multiple canonical transcripts due to overlapping genes. For these cases, we
assigned one of the ”canonical” transcripts to the variant at random, to avoid making
assumptions about their relative importance. Further overlaps within the same gene,
e.g. a missense variant that is also a splice variant in the same transcript, or a
DNA-binding site that also undergoes a particular post-translational modification
were resolved in the same manner.
As an alternative approach, we obtained the worst consequence in all protein
coding transcripts for each variant, using the ranks of variant consequences by severity
provided by Ensembl (see Table 2.1). In the absence of systematic ranking criteria
for the protein function annotations we used the following order: sites that were
designated as having catalytic activity (”active” sites) were given highest priority in
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overlaps, followed by DNA-binding sites, followed by other types of binding (to metal,
polypeptides, ions), and finally by sites that are known to undergo post-translational
or other regulatory modifications, and trans-membrane sites. Thus, a transmembrane
site with regulatory activity is classified as a regulatory site, while a regulatory site
with DNA-binding activity is classified as DNA-binding. Using these alternate criteria
to group sites does not affect our conclusions (Figure 2.12).
All sources of annotation data are listed in (Table 2.1).
2.4.4 Comparing fitness effects across sets of mutational
opportunities
To assess whether the set of 1.1 million C>T mutational opportunities at highly
methylated CpG sites are systematically different from the other ~90 million exonic
mutational opportunities in their potential fitness effects, we compared the distribu-
tion of CADD scores in the two groups using a Kolmogorov-Smirnov test. We note
that this comparison is likely to be somewhat confounded by differences in mutation
rates, given our finding that CADD scores do not perfectly isolate the effects of selec-
tion from those of variability in mutation rates (Figure 2.13). Since the mutation
rate for highly methylated CpG sites is higher than for other types, they may appear
somewhat less constrained than they actually are.
We further compared the fraction of C>T mutational opportunities at highly
methylated CpGs in an annotation class vs. the fraction of other mutational op-
portunities in that class. We used a Fisher exact test (with a Bonferroni correction
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for four tests) to determine whether the two sets of mutational opportunities were
differently distributed across synonymous, missense, regulatory, and LOF variant
classes.
2.4.5 Obtaining mean de novo mutation rates by mutation
type and annotation
We counted the total number of de novo mutations in sequenced exons (~91 million
mutational opportunities) for 8 classes of mutations: two transitions and a transver-
sion each at C and T sites, transitions at CpG sites with relatively low levels of
methylation (i.e., methylated < 70% of the time in testes and ovaries, measured by
bisulfite sequencing), and transitions at CpG sites with high levels of methylation
(>=70% of the time). To obtain the mutation rate per site per generation, we di-
vided the counts by the haploid sample size (2×2976 individuals) and the number of
mutational opportunities of each type. We report 95% confidence intervals assum-
ing a Poisson distribution for mutation counts. The rates (Figure 2.5) are roughly
consistent with rates predicted by the gnomAD mutation model [13], and similar to
previous estimates [22, 21]. We note that an implicit assumption is that the distri-
bution of parental ages in the trio data is representative of the parental ages over
the evolutionary history of exome samples, since the mutation rate increases with
paternal and maternal ages.
To evaluate the impact of methylation status on the mutation rate at CpG sites, we
obtained the mean mutation rate for C>T mutations at CpG sites in each methylation
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bin as described above, separately for methylation levels in ovaries and testes. While
there is a limited amount of data, especially for some low-methylation bins, our choice
of cutoff for “highly methylated” seems sensible (Figure 2.6).).
We then calculated the mean mutation rate for highly methylated CpG transi-
tions, for different compartments in the genome, namely in (a) exons and non-exons,
(b) four variant consequence categories: synonymous, missense, regulatory, and LOF
variants, (c) CADD score deciles, and (d) in exons that constitute the first half vs the
second half of genes. In each case, we obtained the total number of de novo mutations
and the Poisson 95% confidence interval around mutation counts in each group, and
divided by the number of mutational opportunities in the group. We tested if the
mutation counts in each compartment were different from the expected counts using
the highly methylated CpG transition rate averaged across all compartments using a
Poisson test (we implicitly assume a small sampling error for the highly methylated
CpG transition rate averaged across all compartments).
2.4.6 Variance in mutation rate at highly methylated CpGs
Although current samples of DNM data are large enough to compare the mean mu-
tation rate at methylated CpGs across the annotation classes we are interested in,
there is not enough data to directly compare variances in mutation rates. To learn
how much variation in mutation rates at highly methylated CpGs may exist across
annotations, we therefore have to rely on a broader set of regions e.g., those that fall
inside and outside exons. Exonic and non-exonic regions differ considerably in epige-
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netic features, replication timing, and the impact of transcription associated damage
and repair; yet, there is no discernable difference in average de novo mutation rates at
methylated CpGs inside and outside sequenced exons (FET p-value = 0.08, Figure
2.8). We also compared the number of double and single de novo hits in exons and
non-exons using a Fisher exact test (p-value = 0.5, Figure 2.8). Since the number
of double hits reflects the variance in mutation rates across sites, these results lend
some support to our assumption of the same distribution of transition rates at highly
methylated CpGs across annotations.
2.4.7 Calculating the fraction of sites segregating by
annotation
For each highly-methylated CpG site in the exome, there are three mutational oppor-
tunities (C>A, C>G, C>T); we focus only on the opportunities for C>T mutations.
For each highly methylated CpG site then, we noted whether or not it was segregating,
or in other words if it had a C>T variant in samples of individuals from gnomAD [13],
the UK Biobank [120], the DiscovEHR collaboration between the Regeneron Genetics
Center and Geisinger Health System [119], and 1000 Genomes Phase 3 [71], processed
as described above, or a combined sample of 390,000 non-overlapping individuals.
Within the set of methylated CpG sites where C>T mutations are synonymous, we
calculated the fraction segregating in each sample of interest. Similarly, for different
subsets of methylated CpGs, namely those in (a) four variant consequence categories:
synonymous, missense, regulatory, and LOF variants, (c) CADD score deciles, (d)
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functional site categories (e.g., trans-membrane vs catalytic sites in proteins), and
(e) the first half vs the second half of genes, we calculated the fraction segregating
in the combined sample of 390,000 individuals. We normalized the fraction of sites
segregating in each annotation by the fraction of synonymous sites segregating in the
sample.
We verified that the differences in the fraction of sites segregating across an-
notations are not due to different effects of linked selection by annotation. To do
so, we calculated the fraction of sites segregating with sites in different annotations
matched for B-statistics [126]; we obtained very similar results with this approach
(Figure 2.11).
We assume that conditional on the number of mutational opportunities and a
fixed probability of segregating for each site in a compartment, the number of sites
segregating is binomially distributed, and obtained 95% confidence intervals on that
basis. We tested if the probability of segregating in each compartment was different
from the probability of segregating at putatively neutral (here, synonymous) sites
using a Binomial test.
We also calculated the fraction of other types of synonymous sites segregating in




We used a forward simulation framework initially described in Simons et al. (2014)
[134], modified in Fuller et al. (2019), and also described in Agarwal, Fuller, and
Przeworski (in prep). Briefly, we modeled evolution at a single non-recombining bi-
allelic site, which undergoes mutations each generation at rate 2Neu in a panmictic
diploid population of effective population size Ne. Each generation is formed by
Wright-Fisher sampling with selection, where fitness is reduced by hs in heterozygotes
and s in homozygotes for the T allele. We fixed the dominance coefficient h as 0.5,
as only the compound parameter hs is important to the dynamics of dominant alleles
(reviewed in Fuller et al. 2019), and we choose one value of s for each simulation.
Given a mutation rate and a demographic model that specifies Ne in each generation,
we simulated the evolution of this locus forward in time to determine whether the
site is segregating in a sample of size n at present.
We used u = 1.2×10-7 to model CpG>TpG mutation at a highly methylated CpG
site. The simulation framework allows for recurrent mutations, which are expected
to arise often at this mutation rate. We also allowed for TpG>CpG back mutations
at the rate of 5×10-9 (calculated from de novo mutation data, as for CpG>TpG
mutations).
We used the Schiffels-Durbin model for population size changes in Europe over the
past ~55,000 generations, preceded by a ~10Ne generation burn-in period of neutral
evolution at an initial population size N e of 14,448 (following Simons et al. 2014).
In the last generation, i.e., at present, we sample n individuals from the simulated
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population, to match the size of the sample of interest.
We calculated the probability that a site with the fixed mutation rate u above is
segregating for a given value of h and s (with s=0 under neutrality) as the proportion
of simulations with those parameters in which the site is segregating for different sam-
ple sizes at present. We also obtained the probability that a neutral site is segregating
if the mutation rate is not fixed but rather drawn from a lognormal distribution with
mean 1.2×10-7, and for different degrees of variance, as described in Harpak et al.
2016 [24].
In comparing the output of these simulations to data, we consider two scenarios
where we may either undercount or overcount segregating CpG sites in the data
relative to the simulations. First, because we condition on the human reference allele
being CpG in data, we do not count sites where the CpG is the ancestral but not
the reference allele. To check how often this is expected to occur, we mimic this
scenario in simulations, sampling a single chromosome at the end of the simulation
as reference. The proportion of simulations in which CpG is the ancestral but not
the reference allele is ~0.1%. The second case is that for a subset of the CpG>TpG
variants observed at present, the CpG mutation is not ancestral, yet we do not include
that case in simulations. To mimic this scenario in our simulations, we simulate a site
that starts as TpG (with a mutation rate of 5×10-9 to CpG, and a back mutation rate
~1.2×10-7 to TpG) forward in time. Then, as above, we draw a single chromosome
from the sample at the end of the simulation and set it as the reference. We obtain
the proportion of simulations in which the C allele is the reference, starting from
a TpG background. Reassuringly, this occurs in only 0.0014% of simulations. We
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note that there is a third scenario, in which ApG or GpG sites is ancestral and a
C/T polymorphism is found in the sample at present as a result of two mutations,
one to T and one to C. Given the various mutation rates involved (all less than 5
×10-9), this double mutation case will be even less likely than the one in which TpG
was ancestral. These rare scenarios should not have any substantive effect on our
comparison of data to simulations, particularly when we only use such comparisons
to examine qualitative trends.
2.4.9 Inferring selection in simulations
In lieu of calculating the probability that a site segregates for a fixed value of s, we
can propose s from a prior distribution and infer the posterior distribution of hs for
a site with a T allele at 0 copies using a simple Approximate Bayesian Computa-
tion (ABC) approach. Specifically, we propose s such that log10(s) ∼ U(−7, 0); we
simulate expected T allele counts under our model for 10 million proposals from the
prior. We accept the subset of the proposed values of s where simulations yield 0
copies of the T allele in the sample at present; this set of s values is a sample from
the posterior distribution of s given that the site is monomorphic. We calculated the
Bayes odds of s >10-3 as the ratio of the posterior odds of s >10-3 and the prior odds
of s >10-3:
p(hs > 5× 10−4 | T=0 )/p(hs ≤ 5× 10−4 | T=0 )
p(hs > 5× 10−4)/p(hs ≤ 5× 10−4)
We similarly obtain posterior distributions of hs (h fixed at 0.5) for sites that
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are segregating at 0, 1-10 copies, or >10 copies, in samples of different sizes, and
for three different choices of priors on s, namely: s ∼ Beta(α = 0.001, β = 0.1);
log(s) ∼ N(−6, 2); and Nes ∼ Gamma(k = 0.23, θ = 425/0.23), with Ne=10,000,
based on the parameters inferred in Eyre-Walker et al. 2006. These are shown in
Figure 2.7).
2.4.10 Coalescent Simulations to obtain the length of
genealogy of large samples
We simulated the genealogy of a sample of varying sizes using msprime [135] under
different demographic histories, modifying the standard Schiffels-Durbin models as
follows:
(a) Demographic history for a sample of Utah residents with Northern and Western
European ancestry (CEU) over 55,000 generations, modified from from Schiffels
and Durbin 2014, with a recent Ne of 10 million for the past 50 generations,
described above.
(b) CEU demographic history for 55,000 generations with a recent Ne of 100 million
for the past 50 generations.
(c) CEU demographic history for 55,000 generations with 5% exponential growth
for the past 200 generations.
(d) Demographic history for a sample of Yoruba (YRI) ancestry from Schiffels and
Durbin 2014, modified with a recent Ne of 10 million for the last 50 generations.
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(e) A structured sample from two populations that derived from an ancestral pop-
ulation with YRI demographic history 2,000 generations ago, with YRI and
CEU demographic histories respectively since, and a recent Ne of 10 million for
the last 50 generations in each.
The code for implementing these different demographic models in msprime is
available as part of the Supplementary Materials. In each case, we recorded the
mean genealogy length over 20 iterations.
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2.5 Supplementary Tables and Figures
Figure 2.5: Exonic de novo mutation rates in a sample of 2976 parent-offspring trios, by
mutation type. Error bars reflect the 95% Poisson confidence interval around mutation
counts for each type.
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Figure 2.6: De novo mutation rates in exons in a sample of 2976 parent-offspring trios, by
average methylation levels in testes and ovarian tissue. Error bars reflect the 95% Poisson
confidence interval around mutation counts in each group (the minimum number of DNMs
in each bin is 5).
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Figure 2.7: Prior on hs (left column) and Bayes odds that s > 0.001 given that a mutation
at a site is observed at 0, 1-10, or >10 copies, for various sample sizes (right column). The
odds are calculated using 10,000 draws from the prior and posterior distributions. h is
fixed at 0.5 (a) s ∼ Beta(α = 0.001, β = 0.1). Values below 10-10 are binned as 10-10. (b)
log(s) ∼ N(−6, 2). (c) Nes ∼ Gamma(k = 0.23, θ = 425/0.23), with Ne=10,000, based on
the parameters inferred in Eyre-Walker et al. 2006.
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Figure 2.8: Comparing the distribution of mutation rates in non-exons and exons (a) DNM
rates for CpG transitions at highly methylated sites in exons vs. non-exons, normalized by
the total DNM rate in the genome, with 95% Poisson confidence intervals. (b) The rate of
single hits (one DNM at a site) and double hits (two DNMs at a site) in exons vs non-exons,
normalized to the average rate of single and double hits in the genome, with 95% Poisson
confidence intervals.
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Figure 2.9: The effect of mutation rate variation on the probability that a site is observed
segregating under neutrality at different sample sizes. Variable mutation rates are modeled
as lognormally distributed with mean1.2×10-7, as described in Harpak et al. 2016.
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Figure 2.10: (a) DNM rates for synonymous and LOF CpG transitions at highly methy-
lated sites in exons that constitute the first vs. second halves of canonical protein coding
transcripts, normalized by the total DNM rate in exons, with 95% Poisson confidence in-
tervals. (b) Fraction of highly methylated CpG sites that are segregating as a synonymous
or LOF C/T polymorphism in exons that constitute the first vs. second halves of canoni-
cal protein coding transcripts, relative to the fraction of all synonymous sites segregating.
Error bars are 95% confidence intervals assuming the number of segregating sites is bi-
nomially distributed (see Methods). LOF variants are defined as stop-gained and splice
donor/acceptor variants that do not fall near the end of the transcript, and meet the other
criteria to be classified as “high-confidence” loss-of-function in gnomAD.
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Figure 2.11: (a) Cumulative distribution of the B-statistic from McVicker et al., 2009 for
all possible CpG transitions at highly methylated sites by annotation class. (b) Fraction of
highly methylated CpG sites that are segregating as a C/T polymorphism in an annotation
class, relative to the fraction of synonymous sites segregating, after matching the distri-
bution of the B-statistic across annotations. The fraction segregating without matching
for B-statistics is denoted by crosses, to enable comparison to Figure 2.3. Regulatory
variants include non-LOF splice region variants and UTRs. (c) Cumulative distribution
of the B-statistic for all possible CpG transitions at highly methylated sites by functional
class. (d) The proportion of synonymous and missense segregating C/T polymorphisms for
four functional classes, after matching the distribution of the B-statistic across categories.
Error bars are 95% confidence intervals assuming the number of segregating sites is bino-
mially distributed. The fraction segregating without matching for B-statistics is denoted
by crosses, to enable comparison to Figure 2.3.
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Figure 2.12: The analyses in Figure 2.3, but with annotations obtained using the worst
consequence in protein coding transcripts by severity, instead of canonical transcripts; the
order of preference by which functional sites are assigned to a single category is detailed in
Methods.
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Figure 2.13: (a) De novo C>T mutation rate at highly methylated CpGs in deciles of
CADD scores in exons, normalized by the total rate of highly methylated CpG transitions
in exons. Error bars reflect the 95% Poisson confidence interval around mutation counts
in each group. (b) Fraction of highly methylated CpG sites that are segregating as a C/T
polymorphism in a CADD score decile, relative to the fraction of synonymous sites segregat-
ing. (c) The same as (a) but for C>T mutations at all CpG sites, including unmethylated
and less methylated CpGs as well as highly methylated ones. (d) The same as (b) but for
C>T mutations at all CpG sites.
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Figure 2.14: Cumulative distribution of the B-statistic from McVicker et al., 2009 for
highly methylated CpG sites vs. all other types of sites in exons (ks test p-value < 10-5).
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Figure 2.15: (a) The expected number of neutral mutations in a sample, for three mutation
rates, calculated as the expected length of the genealogy (averaged over 20 simulations) for
a CEU sample ×mutation rate. (b) A comparison of mean tree lengths for four variations
on the Schiffels-Durbin demographic models for CEU and YRI populations, namely, YRI
demographic history with a recent Ne of 10 million for the last 50 generations, CEU demo-
graphic history for 50,000 generations with a recent Ne of 10 million or 100 million, and
CEU demographic history with 5% exponential growth for the past 200 generations. (b) A
comparison of mean tree lengths for samples from YRI and CEU populations, and samples
from a structured population derived from an ancestral population 2,000 generations ago.
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Figure 2.16: For various sample sizes, the Bayes odds of s > 0.001 (h=0.5) for a mutation
observed at 0, 1-10, or >10 copies, where the prior distribution of s is log-uniform over
[10-7,1]. The odds are calculated from 15,000 draws from the prior and posterior distribu-
tions (a) At a site with mutation rate ~ 10-9 (b) At a site with mutation rate ~ 10-8.
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Figure 2.17: (a) Distribution of CADD scores for 1.1 million mutational opportunities
for CpG transitions vs. 90 million other mutational opportunities in exons (p-value from
a Kolmogorov-Smirnov test << 10-5). (b) Fraction of mutational opportunities for CpG
transitions vs. all other mutational opportunities in exons by their putative functional
effect. The difference is statistically significant for missense, regulatory, and synonymous
categories (Fisher exact test p-value << 10-5) but not for the LOF class (p-value=0.06).
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The availability of hundreds of thousands of human whole exome and whole genome
sequences has made it possible to observe human genetic variation on an unprece-
dented scale, and in many cases, to infer evolutionary parameters of interest [9, 10, 11].
The distribution of fitness effects at sites in the genome, for instance, has long been
of great interest to evolutionary biologists as well as human geneticists [7]. Current
samples are already sufficiently large to directly infer the strength of selection from
patterns of observed genetic variation for loss-of-function (LOF) variants in genes:
these estimates have proven useful in triaging genetic causes of undiagnosed severe
childhood diseases [123, 136]. LOF variants are a special case where each gene can be
treated as a single locus at which many possible LOF mutations have the same fitness
impact: the rate at which average entire gene experiences loss-of-function events is
~10-6 per generation, large relative to the genealogical history of current samples, and
almost ten-fold greater than the most mutable sites in the genome. As discussed in
Chapter 2, the distribution of fitness effects at ~1 million highly methylated CpG
sites in the exome, and by proxy, at other sites in exons, should be within reach with
samples of a few million individuals. A more precise characterization of mutation rate
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variation within the class of methylated CpGs (and a reliable demographic model)
will be needed to infer the strength of selection at these sites, however.
With regard to characterizing the sources of mutation for CpGs as well as other
types of sites, identifying germline mutational signatures associated with particular
damage and repair mechanisms promises to yield valuable insights. In addition to
distributions of biochemical markers in the genome, some examples of which are high-
lighted in Chapter 1, patterns of strand-asymmetry in genetic variation can be used
to identify signatures of damage and repair associated with transcription and repli-
cation [137]. As ever-increasing amounts of functional information from human cell
lines, tumor samples, and model organisms (e.g., [138]) becomes available, statistical
approaches that systematically identify mutational signatures in polymorphism data
[139] and interpret them in the light of this functional information will be immensely
valuable in elucidating the kinds of mutational processes active in the germline and
their contributions to mutation rate variation for different mutation types.
Moreover, as the number of parent-offspring trios sequenced increases, it should
become possible to estimate de novo mutation rates for an increasing, though still
limited, number of broad mutational contexts – as we showed in Chapter 2, this is
already extremely useful for different subsets of CpG sites. More importantly, inter-
individual variation in de novo mutations and the dependence of different types of
mutations on sex and age is a promising source of insights into mutational mechanisms
[49]. Because de novo mutations reflect one generation of germline development,
learning more about the biological processes of germline development – for instance,
the number of cell divisions at different stages of development, and the trajectory of
115
methylation and time series information on other biochemical features of germ cells –
and how they differ in males and females with age will help inform our understanding
of how different types of mutations arise during development. Finally, at least some
variation in polymorphism levels at different sites in the genome is attributable to
mutation rates having varied over evolutionary time, and even on relatively short
time scales [110, 52, 111, 112]. Understanding how much this has contributed to the
distribution of diversity for different mutation types will be of relevance in interpreting
signatures of mutational processes in polymorphism data [140]. In summary, both
characterizing the sources of mutation and inferring fitness effects in the genome
will benefit from development of models that capture mutation rate variation over
the genome and over different time scales, as well as from increasing amounts of
functional and genetic variation data.
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